<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><title>Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo - Kong - 2016 - British Journal of Pharmacology - Wiley Online Library</title><meta name="robots" content="noarchive" /><meta http-equiv="X-UA-Compatible" content="IE=7,IE=9,IE=10,IE=11,IE=12,chrome=1" /><!-- START Google Scholar --><meta xmlns="http://www.w3.org/1999/xhtml" name="article_references" content="Kong, J,Chuddy, J,Stock, I A,Loria, P M,Straub, S V,Vage, C,Cameron, K O,Bhattacharya, S K,Lapham, K,McClure, K F,Zhang, Y,Jackson, V M,2016,Pharmacological characterization of the first in class clinical candidate PF&#x2010;05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose&#x2010;dependent insulin secretion ex vivo,British Journal of Pharmacology,173:1452-1464,doi:10.1111/bph.13439." /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_abstract_html_url" content="http://onlinelibrary.wiley.com/doi/10.1111/bph.13439/abstract" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="Kong, J" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="Chuddy, J" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="Stock, I A" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="Loria, P M" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="Straub, S V" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="Vage, C" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="Cameron, K O" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="Bhattacharya, S K" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="Lapham, K" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="McClure, K F" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="Zhang, Y" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author" content="Jackson, V M" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_author_institution" content="Pfizer Worldwide Research and Development Cardiovascular and Metabolic Diseases Research Unit Cambridge MA USA" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_doi" content="10.1111/bph.13439" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_firstpage" content="1452" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_fulltext_html_url" content="http://onlinelibrary.wiley.com/doi/10.1111/bph.13439/full" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_issn" content="1476-5381" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_issue" content="9" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_journal_title" content="British Journal of Pharmacology" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_language" content="en" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_lastpage" content="1464" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_online_date" content="2016/03/17" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_pdf_url" content="http://onlinelibrary.wiley.com/doi/10.1111/bph.13439/pdf" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_publication_date" content="2016/05/01" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_title" content="Pharmacological characterization of the first in class clinical candidate PF&#x2010;05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose&#x2010;dependent insulin secretion ex vivo" /><meta xmlns="http://www.w3.org/1999/xhtml" name="citation_volume" content="173" /><!-- END Google Scholar --><link rel="stylesheet" type="text/css" media="screen" href="http://onlinelibrarystatic.wiley.com/css/importAll.css" /><!--<link rel="stylesheet" type="text/css" media="screen" href="http://onlinelibrarystatic.wiley.com/css/funcChemArticle.css" />--><link rel="stylesheet" type="text/css" media="screen" href="http://onlinelibrarystatic.wiley.com/css/chosen.css" /><link rel="stylesheet" type="text/css" media="print" href="http://onlinelibrarystatic.wiley.com/css/print.css" /><!--[if IE 6]>
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com/css/ie6.css" type="text/css" media="screen,print" />
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com/css/simpleForm_ie6.css" type="text/css" media="screen,print" />
    <![endif]--><!--[if IE 7]>
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com/css/ie7.css" type="text/css" media="screen" />
	   <link rel="stylesheet" href="http://onlinelibrarystatic.wiley.com/css/simpleForm_ie7.css" type="text/css" media="screen,print" />
    <![endif]--><script type="text/javascript" xml:space="preserve">
    //<![CDATA[
    var wol1datalayer = window.wol1datalayer ? wol1datalayer : {};
        

wol1datalayer.channel="JOURNALS"
wol1datalayer.events="event12"
wol1datalayer.pageName=""
wol1datalayer.prop1="FULLTEXT"
wol1datalayer.prop10="Free"
wol1datalayer.prop11="PDF and HTML"
wol1datalayer.prop12="69"
wol1datalayer.prop13="10.1111/(ISSN)1476-5381"
wol1datalayer.prop14="10.1111/bph.13439"
wol1datalayer.prop15="10.1111/bph.v173.9"
wol1datalayer.prop18="19 JAN 2016"
wol1datalayer.prop2="FULLTEXT_HTML"
wol1datalayer.prop20=""
wol1datalayer.prop26="Guest"
wol1datalayer.prop28="Regional Provision"
wol1datalayer.prop3="British Journal of Pharmacology"
wol1datalayer.prop4="MDM0,CH60,MD00,MD12,MD19,MDM2,MDM3"
wol1datalayer.prop5=""
wol1datalayer.prop6=""
wol1datalayer.prop7="Pharmacological characterization of the first in class clinical candidate PF\u201005190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose\u2010dependent insulin secretion ex vivo"
wol1datalayer.prop8="173/9"
wol1datalayer.prop9="Free"
wol1datalayer.server="onlinelibrary.wiley.com"


     //]]>
    </script><script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-38b34bd2454506b758d810fab1db811169006b75.js" xml:space="preserve"></script><script type="text/javascript" xml:space="preserve">
        document.documentElement.className = "js_en";
    </script><script language="javascript" xml:space="preserve"> var gs_channels = "default"; </script><script language="javascript" type="text/javascript" src="http://wiley.grapeshot.co.uk/main/channels.cgi?url=http://onlinelibrary.wiley.com/doi/10.1111/bph.13439/full" xml:space="preserve">
    </script><!-- BEGIN Krux Control Tag for "Wiley" --><!-- Source: /snippet/controltag?confid=JMOONjNh&site=Wiley&edit=1 --><script class="kxct" data-id="JMOONjNh" data-timing="async" data-version="1.9" type="text/javascript" xml:space="preserve">
    //<![CDATA[
        window.Krux||((Krux=function() {Krux.q.push(arguments)}).q=[]);
        (function() {
            var k=document.createElement('script');k.type='text/javascript';k.async=true;
            var m,src=(m=location.href.match(/\bkxsrc=([^&]+)/))&&decodeURIComponent(m[1]);
            k.src = /^https?:\/\/([a-z0-9_\-\.]+\.)?krxd\.net(:\d{1,5})?\//i.test(src) ? src : src === "disable" ? "" : (location.protocol==="https:"?"https:":"http:")+"//cdn.krxd.net/controltag?confid=JMOONjNh";
            var s=document.getElementsByTagName('script')[0];s.parentNode.insertBefore(k,s);
        }());

    //]]>
    </script><!-- END Krux Controltag --><!-- START Krux GPT O&O --><script xml:space="preserve">
    //<![CDATA[
    window.Krux||((Krux=function(){Krux.q.push(arguments);}).q=[]);
        (function() {
            function retrieve(n) {
                var m, k='kx'+n;
                if (window.localStorage) {
                    return window.localStorage[k] || "";
                } else if (navigator.cookieEnabled) {
                    m = document.cookie.match(k+'=([^;]*)');
                    return (m && unescape(m[1])) || "";
                } else {
                    return '';
                }
             }
             Krux.user = retrieve('user');
             Krux.segments = retrieve('segs') && retrieve('segs').split(',') || [];
      })();
    //]]>
    </script><!-- END Krux GPT O&O --><script type="text/javascript" xml:space="preserve">
             var googletag = googletag || {};
             googletag.cmd = googletag.cmd || [];
    
             (function() {
               var gads = document.createElement('script');
               gads.async = true;
               gads.type = 'text/javascript';
    
               var useSSL = 'https:' == document.location.protocol;
               gads.src = (useSSL ? 'https:' : 'http:')+'//www.googletagservices.com/tag/js/gpt.js';
    
               var node = document.getElementsByTagName('script')[0];
               node.parentNode.insertBefore(gads, node);
             })();
        </script><script type="text/javascript" xml:space="preserve">
           //<![CDATA[
           googletag.cmd.push(function() {
                googletag.defineSlot('/2215/wly.pharm.med_000096/bj-pharma_BPH', [[160,600],[160,320],[160,160],[120,600]],'advert-job')
                    .addService(googletag.pubads())
                    
                googletag.defineSlot('/2215/wly.pharm.med_000096/bj-pharma_BPH', [728, 90],'advert-leaderboard')
                    .addService(googletag.pubads())
            
                googletag.defineSlot('/2215/wly.pharm.med_000096/bj-pharma_BPH', [160,700],'advert-skyscraper')
                    .addService(googletag.pubads())
                
                googletag.pubads()
                    .setTargeting('WOL-Page-Type', wol1datalayer.prop1)
                    .setTargeting('WOL-Page-Subtype', wol1datalayer.prop2)
                    .setTargeting('WOL-Subject-Codes', wol1datalayer.prop4)
                    .setTargeting('WOL-Article-Access-State', wol1datalayer.prop9)
                    .setTargeting('WOL-Pub-Access-Status', wol1datalayer.prop10)
                    .setTargeting('WOL-Article-Availability', wol1datalayer.prop11)
                    .setTargeting('WOL-Journal-DOI', wol1datalayer.prop13)
                    .setTargeting('WOL-Article-Chapter-DOI', wol1datalayer.prop14)
                    .setTargeting('WOL-Issue-DOI', wol1datalayer.prop15)
                    .setTargeting('WOL-User-login-Status', wol1datalayer.prop26)
                    .setTargeting('gs_cat', gs_channels) // FOR Grapeshot
                    .setTargeting('ksg', Krux.segments) // Krux
                    .setTargeting('kuid', Krux.user); // Krux
    
                googletag.pubads().enableSingleRequest();
                googletag.enableServices();
            });
            //]]>
        </script><!-- END GPT code --><script src="http://content.readcube.com/wiley/epdf_linker.js" type="text/javascript" async="true" xml:space="preserve"></script><link rel="stylesheet" type="text/css" media="screen,print" href="http://onlinelibrarystatic.wiley.com/css/fullText.css" /></head><body><div class="page-wrap">     <div id="skip"><a href="#content">Skip to Main Content</a></div>   <!-- BEGIN #header --> <div id="header">     <div class="ribbon">         <span class="ribbon__quarter ribbon__first"></span>         <span class="ribbon__quarter ribbon__second"></span>         <span class="ribbon__quarter ribbon__third"></span>         <span class="ribbon__quarter ribbon__fourth"></span>     </div>     <div class="l-header-container">         <div class="l-header">              <div class="header-logo">               <a href="/" title="return to home page">                <img src="http://onlinelibrarystatic.wiley.com/images/wolSiteLogo.png" alt="Wiley Online Library" width="182" height="18" />               </a>              </div>                           <div class="header-user-access">            <i class="header-user-access__user icons-user-access-user"></i>            <a href="#" class="js-header-user-access__trigger">Log in / Register<i class="header-user-access__arrow icons-user-access-arrow"></i></a>         </div>          <div id="login">             <form method="post" data-val-form="login" action="/j_spring_security_check" id="loginForm" enctype="application/x-www-form-urlencoded"><fieldset>                     <legend>Log In</legend>                     <div id="loginInFormInner">                         <label for="loginEmail" id="emailLabel">E-Mail Address</label>                         <input type="text" data-val-type="email" id="loginEmail" name="j_username" value="E-Mail Address" />                         <div>                              <label for="loginPassword" id="passwordLabel">Password</label>                              <input type="password" data-val-type="password" id="loginPassword" name="j_password" value="Password" />                              <p class="forgotpass"><a href="/user/forgottenpassword" id="forgottenPassword">Forgotten Password?</a></p>                              <input name="submit" id="loginSubmit" data-val-button="login" type="submit" alt="Go" value="Log In" />                          </div>                         <div id="rememberMeBox">                             <label for="loginRememberMe" class="mailbox__auth__remember">                                     <input type="checkbox" id="loginRememberMe" name="_spring_security_remember_me" checked="checked" /> Remember Me                             </label>                         </div>                     </div>                 </fieldset></form>             <ul id="loginOptions"><li><a href="/user-registration">Register</a></li><li id="lastOpt"><a href="/login-options">Institutional Login</a></li></ul>                                           </div>       <div id="coBranding"> </div>         </div>     </div>  <!-- languageSwitch.ftl -->  </div> <!-- END #header -->     <div id="leftBorder">                 <div id="rightBorder" class="bordered">     <div id="advert-leaderboard">         <script type="text/javascript" xml:space="preserve">     
            googletag.cmd.push(function() { googletag.display('advert-leaderboard'); });        
        </script>         <noscript><a href="http://wiley.grapeshot.co.uk/main/redirect.cgi?target=http://pubads.g.doubleclick.net/gampad/jump?iu=/2215/wly.pharm.med_000096/bj-pharma_BPH;sz=728x90;tile=1;pos=1;doi=101111bph13439;c=1808129618" target="_blank">
                <img src="http://wiley.grapeshot.co.uk/main/redirect.cgi?target=http://pubads.g.doubleclick.net/gampad/ad?iu=/2215/wly.pharm.med_000096/bj-pharma_BPH;sz=728x90;tile=1;pos=1;doi=101111bph13439;c=1808129618" border="0" alt="Advertisement" />
            </a></noscript>     </div> <div id="breadcrumb">          <ul xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns="http://www.w3.org/1999/xhtml"><li><a href="/">Home</a> &gt; </li><li><a href="/subject/code/000096">Pharmacology &amp; Pharmaceutical Medicine</a> &gt; </li><li><a href="/subject/code/MDM0/titles">Pharmacology &amp; Pharmaceutical Medicine</a> &gt; </li><li><a href="/journal/10.1111/(ISSN)1476-5381">British Journal of Pharmacology</a> &gt; </li><li><a href="/doi/10.1111/bph.v173.9/issuetoc">Vol 173 Issue 9</a> &gt; </li><li><a href="/doi/10.1111/bph.13439/abstract">Abstract</a></li></ul> </div>  <div id="pageNavAndTools">               <div class="menuGroup">     <h2>JOURNAL TOOLS</h2>     <ul class="titleTools"><li>                     <a href="/getEmailAlert?id=10.1111%2F%28ISSN%291476-5381&amp;originUrl=%2Fdoi%2F10.1111%2Fbph.13439%2Ffull" class="getEmailAlerts authReq">Get New Content Alerts</a>         </li><li>             <a class="rss" href="/rss/journal/10.1111/(ISSN)1476-5381">Get RSS feed</a>         </li><li>                 <a href="/saveTitle?id=10.1111%2F%28ISSN%291476-5381&amp;type=JOURNAL&amp;originUrl=%2Fdoi%2F10.1111%2Fbph.13439%2Ffull" class="saveToProfile">Save to My Profile</a>         </li><li>                 <a href="/doi/10.1111/bph.v173.1/issuetoc" class="getSampleCopy">Get Sample Copy</a>             </li><li>                 <a class="recommendToLibrarian" href="/recommend/to/librarian/doi/10.1111/(ISSN)1476-5381">Recommend to Your Librarian</a>             </li></ul> </div>             <div xmlns="http://www.w3.org/1999/xhtml" class="menuGroup"><h2>JOURNAL MENU</h2><ul><li><a href="/journal/10.1111/(ISSN)1476-5381">Journal Home</a></li></ul></div><div xmlns="http://www.w3.org/1999/xhtml" class="menuGroup"><h3>FIND ISSUES</h3><ul><li><a href="/journal/10.1111/(ISSN)1476-5381/currentissue" id="currentIssueLink">Current Issue</a></li><li><a href="/journal/10.1111/(ISSN)1476-5381/issues">All Issues</a></li><li><a href="/journal/10.1111/(ISSN)1476-5381/homepage/virtual_issues.htm" title="Virtual Issues">Virtual Issues</a></li></ul></div>                 <div class="menuGroup">         <h3>FIND ARTICLES</h3>         <ul><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/earlyview" id="earlyViewLink">Early View</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/accepted" id="acceptedArticlesLink">Accepted Articles</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/reviews.htm">Reviews</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/MostAccessed.html">Most Accessed</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/MostCited.html">Most Cited</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/EditorsChoice.html">Editors' Choice</a></li></ul>     </div>                 <div class="menuGroup">         <h3>GET ACCESS</h3>          <ul><li>                   <a href="http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1476-5381&amp;doi=10.1111/(ISSN)1476-5381">Subscribe / Renew</a>                </li></ul>     </div>                  <div class="menuGroup">         <h3>FOR CONTRIBUTORS</h3>         <ul><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/FundedAccess.html">Open Access</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/ForAuthors.html">Author Guidelines</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/ForReferees.html">For Referees</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://mc.manuscriptcentral.com/bjp" target="_blank">Submit an Article</a></li></ul>     </div>                  <div class="menuGroup">         <h3>ABOUT THIS JOURNAL</h3>         <ul><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/Society.html">Society Information</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/News.html">News</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/ProductInformation.html">Overview</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/EditorialBoard.html">Editorial Board</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/Permissions.html">Permissions</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/Advertise.html">Advertise</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/Contact.html">Contact</a></li></ul>     </div>                  <div class="menuGroup">         <h2>SPECIAL FEATURES</h2>         <ul><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/themed_issues.htm">Themed Issues: Published</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/call_for_papers.htm">Themed Issues: Call for Papers</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/hot_articles.htm">Recent Highlights</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/homepage/iuphar_reviews.htm">IUPHAR Reviews</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/sign_up_for_content_alerts.htm">Sign up for content alerts</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/download_the_bjp_app.htm">Download the BJP App</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://onlinelibrary.wiley.com/doi/10.1111/bph.v172.24/issuetoc">Concise Guide to PHARMACOLOGY 2015/16</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/bjp_policy_editorials.htm">BJP Policy Editorials</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/author_benefits.htm">Author Benefits</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/pre-2009_cover_archive.htm">Cover Archive</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/gold_open_access_-_a_guide.htm">Gold Open Access - A Guide</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="http://www.wileyjobnetwork.com">Wiley Job Network</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/custom_copy.htm">For Editors</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/bjp_annual_prize_for_early_career_researcher_independent_research_fellow.htm">BJP annual prize for Early Career Researcher/Independent Research Fellow</a></li><li xmlns="http://www.w3.org/1999/xhtml"><a href="/journal/10.1111/(ISSN)1476-5381/homepage/Jobs.html">Jobs</a></li></ul>     </div>                  <div id="advert-job">          <script type="text/javascript" xml:space="preserve">
            googletag.cmd.push(function() { googletag.display('advert-job'); });
         </script>         <noscript><a href="http://wiley.grapeshot.co.uk/main/redirect.cgi?target=http://pubads.g.doubleclick.net/gampad/jump?iu=/2215/wly.pharm.med_000096/bj-pharma_BPH;tile=2;pos=1;sz=160x600,160x320,160x160,120x600;doi=101111bph13439;ord=1808129618?" target="_blank">
                <img src="http://wiley.grapeshot.co.uk/main/redirect.cgi?target=http://pubads.g.doubleclick.net/gampad/ad?iu=/2215/wly.pharm.med_000096/bj-pharma_BPH;tile=2;pos=1;sz=160x600,160x320,160x160,120x600;doi=101111bph13439;ord=1808129618?" border="0" alt="Advertisement" />
            </a></noscript>     </div>                  <div id="advert-skyscraper">          <script type="text/javascript" xml:space="preserve">
            googletag.cmd.push(function() { googletag.display('advert-skyscraper'); });
         </script>         <noscript><a href="http://wiley.grapeshot.co.uk/main/redirect.cgi?target=http://pubads.g.doubleclick.net/gampad/jump?iu=/2215/wly.pharm.med_000096/bj-pharma_BPH;tile=4;pos=1;sz=160X700;doi=101111bph13439;ord=1808129618?" target="_blank">
                <img src="http://wiley.grapeshot.co.uk/main/redirect.cgi?target=http://pubads.g.doubleclick.net/gampad/ad?iu=/2215/wly.pharm.med_000096/bj-pharma_BPH;tile=4;pos=1;sz=160X700;doi=101111bph13439;ord=1808129618?" border="0" alt="Advertisement" />
            </a></noscript>     </div>   </div>  <div id="content">     <div xmlns="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" id="banner" style="background-image: url('http://onlinelibrary.wiley.com/store/10.1111/(ISSN)1476-5381/asset/olbannerwallpaper.gif?v=1&amp;s=8635a8e0a9b9e285702f23874bc2cbe8691aac5e')"><img class="left" src="http://onlinelibrary.wiley.com/store/10.1111/(ISSN)1476-5381/asset/olbannerleft.gif?v=1&amp;s=198ba9e64c782a75183a18cb494f9d10ecc901ea" alt="" /><img class="right" src="http://onlinelibrary.wiley.com/store/10.1111/(ISSN)1476-5381/asset/olbannerright.gif?v=1&amp;s=0b2124237bd4227e7991f1ea05cd4bed2496a9ae" alt="" /></div>      <div id="mainContent">                                                                                                          <div xmlns="http://www.w3.org/1999/xhtml" class="citation articleInformationHeader" id="titleMeta"><div id="articleDesc"><p class="articleCategory">RESEARCH PAPER</p><div id="articleTitle"><span class="freeAccess" title="You have free access to this content">You have free access to this content</span><h1 class="articleTitle"><span class="mainTitle">Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion <em>ex vivo</em></span></h1></div><div id="articleMeta"><ol id="authors"><li id="bph13439-cr-0001">J Kong, </li><li id="bph13439-cr-0002">J Chuddy, </li><li id="bph13439-cr-0003">I A Stock, </li><li id="bph13439-cr-0004">P M Loria, </li><li id="bph13439-cr-0005">S V Straub, </li><li id="bph13439-cr-0006">C Vage, </li><li id="bph13439-cr-0007">K O Cameron, </li><li id="bph13439-cr-0008">S K Bhattacharya, </li><li id="bph13439-cr-0009">K Lapham, </li><li id="bph13439-cr-0010">K F McClure, </li><li id="bph13439-cr-0011">Y Zhang and</li><li id="bph13439-cr-0012">V M Jackson<sup>*</sup></li></ol><p id="publishedOnlineDate">Version of Record online: 17 MAR 2016</p><p id="doi">DOI:&nbsp;10.1111/bph.13439</p><p id="copyright" class="copyright">&copy; 2016 The British Pharmacological Society</p></div><div id="articleParent"><p class="articleCategory">             Issue           </p><div id="cover" class="journal"><div class="imgShadow"><img src="http://onlinelibrary.wiley.com/store/10.1111/bph.v173.9/asset/cover.gif?v=1&amp;s=867ab5be2b1f78870fa118b65b580db1a58fefdf" alt="British Journal of Pharmacology" title="British Journal of Pharmacology" /></div></div><div id="metaData"><h2 id="productTitle">British Journal of Pharmacology</h2><div id="issueDetails"><p class="articleDetails"><a href="/doi/10.1111/bph.v173.9/issuetoc"><span id="volumeNumber">Volume 173</span>,  <span id="issueNumber">Issue 9</span>, </a> <span id="issuePages">pages 1452&ndash;1464</span>, <span id="issueDate">May 2016</span></p></div></div></div></div><div class="altmetric-embed" data-link-target="_blank" data-badge-popover="bottom" data-doi="10.1111/bph.13439" data-badge-type="1"></div><br /><div id="additionalInformation"><p class="articleCategory">Additional Information</p><div style="clear: left;"><div id="howToCite"><h4>How to Cite</h4><p id="citation"><cite id="bph13439-cit-0000"><span class="author">Kong, J.</span>, <span class="author">Chuddy, J.</span>, <span class="author">Stock, I. A.</span>, <span class="author">Loria, P. M.</span>, <span class="author">Straub, S. V.</span>, <span class="author">Vage, C.</span>, <span class="author">Cameron, K. O.</span>, <span class="author">Bhattacharya, S. K.</span>, <span class="author">Lapham, K.</span>, <span class="author">McClure, K. F.</span>, <span class="author">Zhang, Y.</span>, and <span class="author">Jackson, V. M.</span> (<span class="pubYear">2016</span>) <span class="articleTitle">Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion <em>ex vivo</em></span>. <span class="journalTitle">British Journal of Pharmacology</span>, <span class="vol">173</span>: <span class="pageFirst">1452</span>&ndash;<span class="pageLast">1464</span>. doi: <a class="accessionId" href="http://dx.doi.org/10.1111/bph.13439" title="Link to external resource: 10.1111/bph.13439">10.1111/bph.13439</a>.</cite></p></div><div id="authorsDetail"><h4>Author Information</h4><ol id="authorsAffiliations" class="singleton"><li class="affiliation"><p>Cardiovascular and Metabolic Diseases Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, USA</p></li></ol><p id="correspondence"><sup>*</sup>  Correspondence Dr V. Margaret Jackson, Cardiovascular, Metabolic, and Endocrine Diseases Research Unit, Pfizer Worldwide Research and Development, 610 Main St, Cambridge, MA 02139, USA. E-mail: <!--TODO: clickthrough URL--><a href="mailto:Margaret.jackson@pfizer.com" title="Link to email address">Margaret.jackson@pfizer.com</a><br /> </p></div><div id="publicationHistoryDetails"><h4>Publication History</h4><ol><li>Issue online: 8 APR 2016</li><li>Version of Record online: 17 MAR 2016</li><li>Accepted manuscript online: 19 JAN 2016 01:56PM EST</li><li>Manuscript Revised: 8 JAN 2016</li><li>Manuscript Accepted: 8 JAN 2016</li><li>Manuscript Received: 16 FEB 2015</li></ol></div></div></div></div>                            </div> <div id="promosAndTools">                      <form method="post" action="/advanced/search/results" id="searchSite" class="searchForm" name="advancedSearchForm" enctype="application/x-www-form-urlencoded"><fieldset>                 <h2>SEARCH</h2>                 <div class="searchCriteria">                     <label for="scope">Search Scope</label>                     <select id="scope" name="scope"><option value="allContent">All content</option><option value="publicationTitles">Publication titles</option><option value="journal">In this journal</option><option value="issue" selected="selected">In this issue</option></select>                     <div>                         <label for="searchText">Search String</label>                         <input type="text" id="searchText" name="query" />                         <input name="searchSubmit2" id="searchSiteSubmit" type="image" src="http://onlinelibrarystatic.wiley.com/images/searchSubmit.png" value="Go" alt="Search" />                     </div>                         <input type="hidden" value="10.1111/bph.13439" name="publicationDoi" />                         <input type="hidden" value="10.1111/bph.v173.9" name="issueDoi" />                         <input type="hidden" value="10.1111/(ISSN)1476-5381" name="titleDoi" />                     <input type="hidden" value="1" name="start" />                     <input type="hidden" value="20" name="resultsPerPage" />                 </div>             </fieldset><ul class="extraSearchOptions"><li><a href="/advanced/search">Advanced &gt;</a></li><li><a href="/myprofile/displaySavedSearches">Saved Searches &gt;</a></li></ul></form>              <form method="post" action="/search/citation/results" id="searchByCitation" class="searchForm" name="citationSearchForm" enctype="application/x-www-form-urlencoded"><fieldset>                 <h2>SEARCH BY CITATION</h2>                  <div class="searchCriteria">                   <div class="volume">                     <label for="volume">Volume:</label>     <input type="text" id="volume" name="volume" value="" class="searchVolume" />                     </div>                    <div class="issue">                      <label for="issue">Issue:</label>     <input type="text" id="issue" name="issue" value="" class="searchIssue" />                     </div>                    <div class="page">                      <label for="page">Page:</label>     <input type="text" id="page" name="page" value="" class="searchPage" />                     </div>                      <input name="citationSearchSubmit" id="citationSearchSubmit" type="image" src="http://onlinelibrarystatic.wiley.com/images/searchSubmit.gif" value="Go" alt="Search" />                  </div>     <input type="hidden" id="publicationDoi" name="publicationDoi" value="10.1111/(ISSN)1476-5381" />           </fieldset></form>                   <div xmlns:w="http://www.wiley.com/namespaces/wiley" class="menuGroup"><h2>ARTICLE TOOLS</h2><ul class="titleTools"><li class="readcubePdf"><a href="/doi/10.1111/bph.13439/epdf" title="Article in pdf format" id="journalToolsPdfLink" class="readcubeEpdfLink">Get PDF (473K)</a><a href="/doi/10.1111/bph.13439/pdf" title="Article in pdf format" id="journalToolsPdfLink" class="readcubePdfLink">Get PDF (473K)</a></li><li class="save"><a href="/saveContent?doi=10.1111%2Fbph.13439&amp;originUrl=%2Fdoi%2F10.1111%2Fbph.13439%2Ffull">Save to My Profile</a></li><li class="email"><a href="/emailArticleLink?doi=10.1111/bph.13439&amp;issueDoi=10.1111/bph.v173.9">E-mail Link to this Article</a></li><li class="citation"><a href="/documentcitationdownload?publicationDoi=10.1111/(ISSN)1476-5381&amp;doi=10.1111/bph.13439&amp;type=journal">Export Citation for this Article</a></li><li><a class="getEmailAlerts authReq" href="/getCitationAlert?id=10.1111%2Fbph.13439&amp;originUrl=%2Fdoi%2F10.1111%2Fbph.13439%2Ffull">Get Citation Alerts</a></li><li class="requestPermissions"><a href="https://s100.copyright.com/AppDispatchServlet?publisherName=Wiley&amp;publication=BPH&amp;title=Pharmacological%20characterization%20of%20the%20first%20in%20class%20clinical%20candidate%20PF-05190457%3A%20a%20selective%20ghrelin%20receptor%20competitive%20antagonist%20with%20inverse%20agonism%20that%20increases%20vagal%20afferent%20firing%20and%20glucose-dependent%20insulin%20secretion%20ex%20vivo&amp;publicationDate=17%20MAR%202016&amp;author=J%20Kong%2CJ%20Chuddy%2CI%20A%20Stock%2CP%20M%20Loria%2CS%20V%20Straub%2CC%20Vage%2CK%20O%20Cameron%2CS%20K%20Bhattacharya%2CK%20Lapham%2CK%20F%20McClure%2CY%20Zhang%2CV%20M%20Jackson&amp;startPage=1452&amp;endPage=1464&amp;copyright=%C2%A9%202016%20The%20British%20Pharmacological%20Society&amp;contentID=10.1111%2Fbph.13439&amp;orderSource=onlinelibrary%7Cwol1%7Cfulltexthtml&amp;orderBeanReset=true" target="_blank" class="rightsLink">Request Permissions</a></li></ul></div>  </div>      <div id="productContent">                         <div xmlns="http://www.w3.org/1999/xhtml" class="tabbedContent"><ul><li><a href="/doi/10.1111/bph.13439/abstract" title="Link to article abstract">Abstract</a></li><li class="active"><span>Article</span></li><li><a href="/doi/10.1111/bph.13439/references" title="Link to article references">References</a></li><li><a href="/doi/10.1111/bph.13439/suppinfo" title="Link to supporting information">Supporting Information</a></li><li><a href="/doi/10.1111/bph.13439/citedby" title="Other articles that have cited this article">Cited By</a></li></ul></div>                  <div xmlns="http://www.w3.org/1999/xhtml" class="viewFullArticleAndPdf"><div class="viewFullArticleAndPdfOptions"><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1111/bph.13439" class="enhancedArticleLink">Enhanced Article (HTML)</a> <a href="/doi/10.1111/bph.13439/epdf" title="Article in pdf format" class="readcubeEpdfLink">Get PDF (473K)</a><a href="/doi/10.1111/bph.13439/pdf" title="Article in pdf format" class="readcubePdfLink">Get PDF (473K)</a></div></div>                        <div xmlns="http://www.w3.org/1999/xhtml" id="fulltext" class="none"><div id="abstract" class="fullTextAbstract"><div class="headingCont"><h3>Abstract</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><div class="section" id="bph13439-sec-0001"><h4>Background and Purpose</h4><div class="para"><p>Ghrelin increases growth hormone secretion, gastric acid secretion, gastric motility and hunger but decreases glucose-dependent insulin secretion and insulin sensitivity in humans. Antagonizing the ghrelin receptor has potential as a therapeutic approach in the treatment of obesity and type 2 diabetes. Therefore, the aim was to pharmacologically characterize the novel small-molecule antagonist PF-05190457 and assess translational pharmacology <em>ex vivo</em>.</p></div></div><div class="section" id="bph13439-sec-0002"><h4>Experimental Approach</h4><div class="para"><p>Radioligand binding in filter and scintillation proximity assay formats were used to evaluate affinity, and europium-labelled GTP to assess functional activity. Rat vagal afferent firing and calcium imaging in dispersed islets were used as <em>native</em> tissues underlying food intake and insulin secretion respectively.</p></div></div><div class="section" id="bph13439-sec-0003"><h4>Key Results</h4><div class="para"><p>PF-05190457 was a potent and selective inverse agonist on constitutively active ghrelin receptors and acted as a competitive antagonist of ghrelin action, with a human <em>K</em><sub>d</sub> of 3&nbsp;nM requiring 4&nbsp;h to achieve equilibrium. Potency of PF-05190457 was similar across different species. PF-05190457 increased intracellular calcium within dispersed islets and increased vagal afferent firing in a concentration-dependent manner with similar potency but was threefold less potent as compared with the <em>in vitro K</em><sub>i</sub> in recombinant overexpressing cells. The effect of PF-05190457 on rodent islets was comparable with glibenclamide, but glucose-dependent and additive with the insulin secretagogue glucagon-like peptide-1.</p></div></div><div class="section" id="bph13439-sec-0004"><h4>Conclusions and Implications</h4><div class="para"><p>Together, these data provide the pharmacological <em>in vitro</em> and <em>ex vivo</em> characterization of the first ghrelin receptor inverse agonist, which has advanced into clinical trials to evaluate the therapeutic potential of blocking ghrelin receptors in obesity and type 2 diabetes.</p></div></div></div><br /><div class="definitionList"><span class="listPairedTitle">Abbreviations</span><dl class="hh"><dt>CI</dt><dd><p>confidence interval</p></dd><dt>[<span class="smallCaps">d</span>-Lys<sup>3</sup>]-GHRP-6</dt><dd><p>[<span class="smallCaps">d</span>-Lys<sup>3</sup>]-growth hormone releasing peptide-6</p></dd><dt>Eu-GTP</dt><dd><p>europium-labelled GTP</p></dd><dt>GLP-1</dt><dd><p>glucagon-like peptide-1</p></dd><dt>[<sup>3</sup>H]-IP</dt><dd><p>tritium labelled inositol phosphate</p></dd><dt>PYY<sub>3&ndash;36</sub></dt><dd><p>peptide YY</p></dd><dt>SPA</dt><dd><p>scintillation proximity assay</p></dd></dl></div><div class="section" id="bph13439-sec-0005"><div class="headingCont"><h3>Tables of Links</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><div class="para"><div class="table"><table class="topbotR"><thead class="vTop"><tr class="rsep"><th class="hLeft" rowspan="1" colspan="1"><b>TARGETS</b></th></tr></thead><tbody class="vTop"><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><a href="http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246" rel="references:http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246">Ghrelin receptor</a></td></tr></tbody></table><table class="topbotR"><thead class="vTop"><tr class="rsep"><th class="hLeft" rowspan="1" colspan="1"><b>LIGANDS</b></th><th class="hLeft" rowspan="1" colspan="1">&nbsp;</th><th class="hLeft" rowspan="1" colspan="1">&nbsp;</th></tr></thead><tfoot><tr><td colspan="3" rowspan="1"><div class="noteGroup"><ol id="footnotes" class="noteGroup custom"><li id="bph13439-note-0020"><div class="text"><p>These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in <!--TODO: clickthrough URL--><a href="http://www.guidetopharmacology.org" title="Link to external resource: http://www.guidetopharmacology.org">http://www.guidetopharmacology.org</a>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson <em>et al.</em>, <a href="#bph13439-bib-0063" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0063">2014</a>) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander <em>et al.</em>, <a href="#bph13439-bib-0001" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0001">2015</a>).</p></div></li></ol></div></td></tr></tfoot><tbody class="vTop"><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><a href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3597" rel="references:http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3597">Ghrelin</a></td><td class="hLeft" rowspan="1" colspan="1"><a href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5194" rel="references:http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5194">GLP-1</a></td><td class="hLeft" rowspan="1" colspan="1"><a href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5012" rel="references:http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5012">Insulin</a></td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><a href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2414" rel="references:http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2414">Glibenclamide</a></td><td class="hLeft" rowspan="1" colspan="1"><a href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1742" rel="references:http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1742">GTP</a></td><td class="hLeft" rowspan="1" colspan="1"><a href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1554" rel="references:http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1554">PYY<sub>3&ndash;36</sub></a></td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><a href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1093" rel="references:http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1093">GHRP-6</a></td><td class="hLeft" rowspan="1" colspan="1"><a href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4207" rel="references:http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4207">GTP&gamma;S</a></td><td class="hLeft" rowspan="1" colspan="1">&nbsp;</td></tr></tbody></table></div></div></div><div class="section" id="bph13439-sec-0006"><div class="headingCont"><h3>Introduction</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><div class="para"><p>Ghrelin is an endogenous 28 amino acid acylated peptide synthesized within the stomach fundus that has been associated with modulating growth hormone secretion, gastric motility, gastric acid secretion and hunger. Acylated ghrelin is the only peripheral hunger-stimulating hormone that is elevated preprandially in plasma, suggesting a role in meal initiation in humans (Cummings <em>et al.</em>, <a href="#bph13439-bib-0020" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0020">2001</a>). Circulating endogenous baseline and pulsatile patterns of total ghrelin are inhibited in obese subjects following gastric bypass surgery (Cummings <em>et al.</em>, <a href="#bph13439-bib-0021" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0021">2002</a>; Roth <em>et al.</em>, <a href="#bph13439-bib-0070" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0070">2008</a>), whereas endogenous levels of acylated ghrelin are reported to be decreased with increased body mass index (Homaee <em>et al.</em>, <a href="#bph13439-bib-0040" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0040">2011</a>; Moradi <em>et al.</em>, <a href="#bph13439-bib-0054" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0054">2011</a>; Dardzi&#x144;ska <em>et al.</em>, <a href="#bph13439-bib-0025" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0025">2014</a>; van Name <em>et al.</em>, <a href="#bph13439-bib-0081" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0081">2015</a>), elevated in obese type 2 diabetics (Rodr&iacute;guez <em>et al.</em>, <a href="#bph13439-bib-0069" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0069">2009</a>) and inversely correlated with insulin sensitivity (Pagotto <em>et al.</em>, <a href="#bph13439-bib-0058" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0058">2002</a>; Barazzoni <em>et al.</em>, <a href="#bph13439-bib-0005" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0005">2007</a>). Conflicting data may be attributed to differences in patient populations used, assays or plasma sample handling (Blatnik and Soderstrom, <a href="#bph13439-bib-0007" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0007">2011</a>; Blatnik <em>et al.</em>, <a href="#bph13439-bib-0008" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0008">2012</a>). Exogenous administration of acylated ghrelin increases blood glucose and decreases insulin levels in both rodents and humans (Broglio <em>et al.</em>, <a href="#bph13439-bib-0009" class="referenceLink" title="Link to bibliographic citations" rel="references:#bph13439-bib-0009 #bph13439-bib-0010 #bph13439-bib-0011 #bph13439-bib-0012 #bph13439-bib-0013">2001, 2002, 2003a, 2003b, 2004</a>; Arosia <em>et al.</em>, <a href="#bph13439-bib-0002" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0002">2003</a>; Dezaki <em>et al.</em>, <a href="#bph13439-bib-0029" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0029">2004</a>; Sun <em>et al.</em>, <a href="#bph13439-bib-0078" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0078">2006</a>), and also inhibits glucose-stimulated insulin secretion (Reimer <em>et al.</em>, <a href="#bph13439-bib-0067" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0067">2003</a>; Dezaki <em>et al.</em>, <a href="#bph13439-bib-0030" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0030">2007</a>; Tong <em>et al.</em>, <a href="#bph13439-bib-0080" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0080">2010</a>) and peripheral insulin sensitivity (Gauna <em>et al.</em>, <a href="#bph13439-bib-0035" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0035">2004</a>; Lucidi <em>et al.</em>, <a href="#bph13439-bib-0049" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0049">2005</a>; Damjanovic <em>et al.</em>, <a href="#bph13439-bib-0024" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0024">2006</a>; Vestergaard <em>et al.</em>, <a href="#bph13439-bib-0082" class="referenceLink" title="Link to bibliographic citations" rel="references:#bph13439-bib-0082 #bph13439-bib-0083 #bph13439-bib-0084">2007, 2008a, 2008b</a>).</p></div><div class="para"><p>Acylated ghrelin is the endogenous ligand for the growth hormone secretagogue receptor 1a (ghrelin receptor; Alexander <em>et al.</em>, <a href="#bph13439-bib-0002" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0002">2003</a>) of which des-acylated ghrelin has no activity. The ghrelin receptor is unique in that it has been shown to be constitutively active, suggesting that blocking ghrelin receptor tone rather than blocking endogenous acylated ghrelin binding may be beneficial (Mear <em>et al.</em>, <a href="#bph13439-bib-0051" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0051">2013</a>). The metabolic effects of acylated ghrelin were originally considered to be acting on central ghrelin receptors as ghrelin crosses the blood brain barrier (Banks <em>et al.</em>, <a href="#bph13439-bib-0004" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0004">2002</a>); however, it is now evident that many of ghrelin's actions are mediated peripherally as the brain-impaired selective ghrelin receptor agonist capromorelin caused insulin resistance in humans (White <em>et al.</em>, <a href="#bph13439-bib-0087" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0087">2009</a>), and ghrelin receptors are located on islets and vagal afferent soma (Gnanapavan <em>et al.</em>, <a href="#bph13439-bib-0036" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0036">2002</a>; Volante <em>et al.</em>, <a href="#bph13439-bib-0085" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0085">2002</a>; Wierup <em>et al.</em>, <a href="#bph13439-bib-0088" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0088">2002</a>; Sakata <em>et al.</em>, <a href="#bph13439-bib-0073" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0073">2003</a>; Kageyama <em>et al.</em>, <a href="#bph13439-bib-0043" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0043">2005</a>; Wierup and Sundler, <a href="#bph13439-bib-0089" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0089">2005</a>; Burdyga <em>et al.</em>, <a href="#bph13439-bib-0014" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0014">2006</a>; Dezaki <em>et al.</em>, <a href="#bph13439-bib-0030" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0030">2007</a>; Sato <em>et al.</em>, <a href="#bph13439-bib-0076" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0076">2007</a>; Jia <em>et al.</em>, <a href="#bph13439-bib-0042" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0042">2008</a>; Damdindorj <em>et al.</em>, <a href="#bph13439-bib-0023" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0023">2012</a>; Grabauskas <em>et al.</em>, <a href="#bph13439-bib-0037" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0037">2015</a>). Ghrelin-induced food intake is blocked by vagotomy in rodents and humans (Date <em>et al.</em>, <a href="#bph13439-bib-0026" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0026">2002</a>; le Roux <em>et al.</em>, <a href="#bph13439-bib-0048" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0048">2005</a>), and ghrelin (i.v.) suppresses vagal afferent firing (Asakawa <em>et al.</em>, <a href="#bph13439-bib-0003" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0003">2001</a>; Date <em>et al.</em>, <a href="#bph13439-bib-0026" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0026">2002</a>, <a href="#bph13439-bib-0027" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0027">2012</a>; Inui <em>et al.</em>, <a href="#bph13439-bib-0041" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0041">2004</a>). Selective blockade of the gastric vagus nerve either by capsaicin (afferent only) or surgical differentiation (afferent and efferent pathways) blocks c-Fos expression within the arcuate nucleus in response to ghrelin-induced feeding. Vagotomy also eliminates ghrelin-induced growth hormone secretion, indicating a novel vagus-mediated growth hormone secretion pathway (Date <em>et al.</em>, <a href="#bph13439-bib-0026" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0026">2002</a>), in addition to the known vagus-mediated efferent regulation of gastrointestinal motility, gastric acid secretion and nausea (Yakabi <em>et al.</em>, <a href="#bph13439-bib-0091" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0091">2008</a>; Sanger <em>et al.</em>, <a href="#bph13439-bib-0075" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0075">2013</a>; Swartz <em>et al.</em>, <a href="#bph13439-bib-0079" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0079">2014</a>).</p></div><div class="para"><p>Whilst the effect of ghrelin and small-molecule agonists have been well characterized pharmacologically and profiled in man, there have been a paucity of reports on the translational pharmacology of ghrelin receptor antagonists comparing potency and efficacy in preclinical models and no published clinical data. Antagonists routinely used preclinically to evaluate ghrelin receptor activity, such as [<span class="smallCaps">d</span>-Arg1,<span class="smallCaps">d</span>-Phe5,<span class="smallCaps">d</span>-Trp7,9,Leu11]-substance P and [<span class="smallCaps">d</span>-Lys<sup>3</sup>]-GHRP-6, are hampered by the fact that they are peptidic or peptidomimetic antagonists with limited potency (&gt;100&nbsp;nM), and selectivity. For example, [<span class="smallCaps">d</span>-Arg1,<span class="smallCaps">d</span>-Phe5,<span class="smallCaps">d</span>-Trp7,9,Leu11]-substance P is a potent bombesin antagonist and [<span class="smallCaps">d</span>-Lys<sup>3</sup>]-GHRP-6 can activate 5-HT receptors and antagonize CCR4/CCR5 receptors, hence limiting their use in translational <em>ex vivo</em> and <em>in vivo</em> experimentation (Woll and Rozengurt, <a href="#bph13439-bib-0090" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0090">1988</a>; Depoortere <em>et al.</em>, <a href="#bph13439-bib-0028" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0028">2006</a>; Patel <em>et al.</em>, <a href="#bph13439-bib-0061" class="referenceLink" title="Link to bibliographic citations" rel="references:#bph13439-bib-0061 #bph13439-bib-0062">2012a, 2012b</a>).</p></div><div class="para"><p>Due to the potential therapeutic utility of ghrelin receptor antagonists, the search for potent selective small-molecule antagonists has been pursued. These molecules have been discovered using recombinant cell lines to evaluate binding and antagonizing ghrelin-induced activation of G<sub>q</sub>-coupled pathways known to underlie growth hormone secretion in the pituitary (Pasternak <em>et al.</em>, <a href="#bph13439-bib-0060" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0060">2009</a>; Perdon&agrave; <em>et al.</em>, <a href="#bph13439-bib-0065" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0065">2011</a>; Mihalic <em>et al.</em>, <a href="#bph13439-bib-0052" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0052">2012</a>; Puleo <em>et al.</em>, <a href="#bph13439-bib-0066" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0066">2012</a>; Alexander <em>et al.</em>, <a href="#bph13439-bib-0002" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0002">2003</a>; Moulin <em>et al.</em>, <a href="#bph13439-bib-0056" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0056">2013</a>; <!--TODO: clickthrough URL--><a href="http://www.iuphar.org" title="Link to external resource: http://www.iuphar.org">www.iuphar.org</a>/)<em>.</em> However, the signal transduction mechanisms mediating the effect of the ghrelin receptor in pancreatic beta cells are distinct from those utilized in GH-releasing and/or ghrelin receptor-expressing cells as demonstrated by the use of pertussis toxin to inhibit the ghrelin-induced inhibition of insulin secretion, suggesting G<sub>i</sub>-mediated pathways maybe more relevant to insulin secretion (Dezaki <em>et al.</em>, <a href="#bph13439-bib-0030" class="referenceLink" title="Link to bibliographic citations" rel="references:#bph13439-bib-0030 #bph13439-bib-0031">2007, 2008</a>; Damdindorj <em>et al.</em>, <a href="#bph13439-bib-0023" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0023">2012</a>). In addition, the ghrelin receptor has been reported to be constitutively active using recombinant <em>in vitro</em> systems, suggesting an inverse agonist rather than a neutral antagonist may be therapeutically relevant; however, this remains to be demonstrated in native tissue or <em>in vivo</em> physiological systems.</p></div><div class="para"><p>The current study reports a potent and selective small-molecule ghrelin receptor competitive antagonist with inverse agonism that is equally potent and efficacious within native physiological systems underlying food intake and insulin secretion <em>ex vivo</em>. A high-throughput screening of the Pfizer corporate compound file led to the identification of a spiro-azetidino piperidine series of analogues (Cameron <em>et al.</em>, <a href="#bph13439-bib-0017" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0017">2014</a>). Medicinal chemistry optimization of initial leads in this series for ghrelin receptor activity while balancing absorption, distribution, metabolism, and excretion and off-target selectivity provided PF-05190457 (2-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)-1-{2-[(1R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1&nbsp;H-inden-1-yl]-2,7-diazaspiro[3.5]non-7-yl}ethanone) (Bhattacharya <em>et al.</em>, <a href="#bph13439-bib-0006" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0006">2014</a>). Based on its promising pharmacological and safety profile, PF-05190457 has advanced into human clinical trials.</p></div></div><div class="section" id="bph13439-sec-0007"><div class="headingCont"><h3>Methods</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><div class="section" id="bph13439-sec-0008"><h4>In vitro radioligand binding, direct and indirect quantitative kinetics</h4><div class="para"><p>The <em>in vitro</em> potency of PF-05190457 (Bhattacharya <em>et al.</em>, <a href="#bph13439-bib-0006" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0006">2014</a>) against the human ghrelin receptor was determined by radioligand binding in two different assay formats: filter plate and scintillation proximity assay (SPA). Both assays utilized membranes prepared from HEK293 cells which had been stably transfected with a tet-inducible construct expressing the human ghrelin receptor. The stable cell lines were grown under Zeocin/blasticidin selection in T-Rex-293 cells (Life Technologies) and receptor expression was induced with doxycycline. Clonal cell lines (human, rat and mouse) and stable cell pools (dog and primate) were evaluated for receptor expression via saturation binding to ensure appropriate receptor expression. <em>B</em><sub>max</sub> and <em>K</em><sub>d</sub> were determined for individual membrane preparations. Control membranes were also prepared from parental T-Rex-293 cells and were negative for [<sup>125</sup>I]-ghrelin binding. Membranes were incubated in the presence of PF-05190457 (1&nbsp;&times;&nbsp;10<sup>&ndash;10</sup>&nbsp;&minus;&nbsp;1&nbsp;&times;&thinsp;10<sup>&ndash;5</sup>&nbsp;M) and a single concentration (~50&nbsp;pM) of human [<sup>125</sup>I]-ghrelin (Perkin Elmer Life Sciences) for either 90&nbsp;min (filter plate) or 8&nbsp;h (SPA) and a <em>K</em><sub>i</sub> value was determined. The binding potency for PF-05190457 against the ghrelin receptor for dog, primate, rat and mouse was also determined by a filter binding assay, using membranes prepared from HEK293 cells which had been transfected with a tet-inducible construct expressing dog, primate, rat or mouse ghrelin receptor. Binding data were analysed using internal software. An IC<sub>50</sub> value was determined using a four-parameter fit algorithm, and the <em>K</em><sub>i</sub> value was generated using the Cheng&ndash;Prusoff equation: <em>K</em><sub>i</sub>&nbsp;=&nbsp;IC<sub>50</sub>/(1&nbsp;+&nbsp;([<em>L</em>]/<em>K</em><sub>d</sub>), where [<em>L</em>] was the actual radioligand concentration in the assay and <em>K</em><sub>d</sub> was the equilibrium dissociation constant specific for the batch of receptor membrane used in the experiment. The <em>K</em><sub>i</sub> values are reported as the geometric mean with 95% confidence interval (CI) for the number (<em>n</em>) of determinations.</p></div><div class="para"><p>The binding kinetics of PF-05190457 was evaluated using both an indirect Motulsky and Mahan method (Motulsky and Mahan, <a href="#bph13439-bib-0055" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0055">1984</a>) and by directly radiolabelling PF-05190457 ([<sup>3</sup>H]-PF-05190457; 3&nbsp;&times;&nbsp;10<sup>&ndash;9</sup>&nbsp;&minus;&nbsp;1&nbsp;&times;&nbsp;10<sup>&ndash;8</sup>&nbsp;M) with a specific activity of 4.9&nbsp;Ci&sdot;mmol<sup>&minus;1</sup> and &gt;98% radiochemical purity, provided by Groton Radiochemistry Laboratory (see modelling methodology in Supporting Information 2S). Using the indirect method, [<sup>125</sup>I]-ghrelin 0.25&nbsp;nM was profiled with and without PF-05190457 (1&nbsp;&times;&nbsp;10<sup>&ndash;9</sup>&nbsp;&minus;&nbsp;1&nbsp;&times;&nbsp;10<sup>&ndash;7</sup>&nbsp;M) over a 7&nbsp;h period to evaluate the association and dissociation rate for PF-05190457. A saturation binding was also performed under these conditions to obtain the <em>K</em><sub>d</sub> of PF-05190457.</p></div></div><div class="section" id="bph13439-sec-0009"><h4>Europium-labelled GTP functional in vitro assay</h4><div class="para"><p>The functional activity of PF-05190457 was determined using a Eu-GTP assay on membranes prepared from HEK293 cells stably transfected with the human ghrelin receptor. Membranes were incubated in the presence PF-05190457 (3&nbsp;&times;&nbsp;10<sup>&ndash;11</sup>&nbsp;&minus;&nbsp;1&nbsp;&times;&nbsp;10<sup>&ndash;4</sup>&nbsp;M) with and without an 80% maximal effective concentration of human acylated ghrelin (1.5&nbsp;nM; AnaSpec) for 114&nbsp;min. PF-05190457 was profiled as an agonist, partial agonist or inverse agonist in the absence of ghrelin, whereas the antagonist mode measured the ability of PF-05190457 to block the ghrelin-stimulated changes. To evaluate the competitive antagonist nature of PF-05190457, membranes were incubated in the presence human acylated ghrelin (1&nbsp;&times;&nbsp;10<sup>&ndash;11</sup>&nbsp;&minus;&nbsp;3&nbsp;&times;&nbsp;10<sup>&ndash;6</sup>&nbsp;M) with or without a single concentration of PF-05190457 (1&nbsp;&times;&nbsp;10<sup>&ndash;9</sup>&nbsp;&minus;&nbsp;1&nbsp;&times;&nbsp;10<sup>&ndash;5</sup>&nbsp;M) pre-incubated for 2&nbsp;h. The relative fluorescence unit of membrane-bound Eu-GTP was determined by an EnVision Mutilabel Reader (PerkinElmer). To generate a Schild Plot, a graph with log of antagonist concentration on the <em>x</em>-axis and log of &lsquo;concentration ratio &minus;1&rsquo; on the <em>y</em>-axis was plotted by using the Graphpad Prism programme (GraphPad Software, Inc).</p></div></div><div class="section" id="bph13439-sec-0010"><h4>Rat stomach&ndash;gastric vagus preparation and unit action potential recording <em>ex vivo</em></h4><div class="para"><p>Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny <em>et al.</em>, <a href="#bph13439-bib-0046" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0046">2010</a>; McGrath and Lilley, <a href="#bph13439-bib-0050" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0050">2015</a>). Male Sprague Dawley rats (Charles River, ~150&ndash;250&nbsp;g/2- to 3-months-old; group housed), with <em>ad libitum</em> access to normal chow and water, were anaesthetized with an i.p. injection of Nembutal sodium (0.4&ndash;0.6&nbsp;mL of 50&nbsp;mg&sdot;mL<sup>&minus;1</sup> Nembutal sodium solution) prior to decapitation. All experiments were performed in accordance with Institutional Animal Care and Use Committee guidelines and regulations at Pfizer Inc. (Groton, CT). Rats were used as the pharmacological model of choice as (i) there are no known species differences in rodent physiology and (ii) to align with toxicology species as PF-05190457 is a clinical candidate. To ensure replacement, refinement or reduction of animals, tissue harvesting was shared amongst groups, and preclinical statistics was involved in experimental design in addition to analysis of all <em>ex vivo</em> studies. Experiments were conducted on an isolated rat stomach gastric vagus nerve <em>ex vivo</em> preparation, as previously described (Wei and Wang, <a href="#bph13439-bib-0086" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0086">2000</a>). The esophagus and stomach were pinned to a Sylgard (Dow Corning)-filled dissection dish, and the tissue was rinsed several times with ice cold recording buffer that contained 134.7&nbsp;mM NaCl, 16.3&nbsp;mM NaHCO<sub>3</sub>, 3.4&nbsp;mM KCl, 1.3&nbsp;mM KH<sub>2</sub>PO<sub>4</sub>, 2.8&nbsp;mM CaCl<sub>2</sub>, 0.6&nbsp;mM MgSO<sub>4</sub> and 7.7&nbsp;mM glucose and continuously bubbled with 95% O<sub>2</sub>/5% CO<sub>2</sub>. The vagal nerves and surrounding connective tissue were carefully dissected free from the oesophagus and pinned out. A piece of connective tissue was attached to the left platinum electrode wire (0.25&nbsp;mm diameter; World Precision Instruments), and several nerve fibres were wrapped around the right electrode wire. The platinum wires were connected to an NL-100 headstage (NeuroLog) which was connected to an NL-104 pre-amplifier. The signal was filtered through an NL 125/126 filter which was set at 200&nbsp;Hz and 3&nbsp;kHz. The signal from the NeuroLog was passed through a HumBug filter (Quest Scientific) and acquired using <span class="smallCaps">l</span>ab<span class="smallCaps">c</span>hart software (version 7.0.1, AD Instruments) via a PowerLab 4/30&nbsp;A-D interface (AD Instruments) sampling at 20&nbsp;kHz. The recording buffer was perfused at a rate of ~10&nbsp;mL&sdot;min<sup>&minus;1</sup> via a peristaltic pump, and heated to 35&deg;C via an electronically controlled in-line solution heater (TC344B, Warner Instruments). To ensure that the level of spontaneous afferent nerve activity was stable, spontaneous activity was recorded for ~20&nbsp;min at the beginning of each experiment prior to intragastric arterial infusion of increasing concentrations of PF-05190457 (1&nbsp;&times;&nbsp;10<sup>&ndash;10</sup>&nbsp;&minus;&nbsp;1&nbsp;&times;&nbsp;10<sup>&ndash;6</sup>&nbsp;M) or the neutral antagonist compound 2 (1&nbsp;&times;&nbsp;10<sup>&ndash;10</sup>&nbsp;&minus;&nbsp;1&nbsp;&times;&nbsp;10<sup>&ndash;6</sup>&nbsp;M) (Supporting Information Figure 1S). Each drug concentration-effect was allowed to plateau prior to addition of a higher drug concentration (circa 10&ndash;15&nbsp;min). Nerve recordings were analysed using <span class="smallCaps">l</span>ab<span class="smallCaps">c</span>hart software, and action potentials were detected using the simple threshold analysis detection function. Firing frequency was expressed as mean&nbsp;&plusmn;&nbsp;SD. For each individual experiment, the total nerve activity generated over a 5&nbsp;min period sampled 5&nbsp;min after injection of 0.3&nbsp;mL of control recording solution (basal activity) was subtracted from all drug-treated responses, and the responses were then normalized to the maximum activity elicited during the experiment. Normalized data from all experiments were averaged and plotted as a concentration&ndash;response curve, which was fit using the log [agonist] versus response function within <span class="smallCaps">g</span>raphpad <span class="smallCaps">p</span>rism to generate a concentration of PF-05190457 required for 50% inhibition. EC<sub>50</sub> values are reported as mean&nbsp;&plusmn;&nbsp;SEM.</p></div></div><div class="section" id="bph13439-sec-0011"><h4>Rat dispersed islets and single cell calcium imaging</h4><div class="para"><p>Male Sprague Dawley rats (~275&nbsp;g/~3&nbsp;months old; group housed) were killed by CO<sub>2</sub> and cervical dislocation, the pancreas was removed and islet cells were isolated as previously described (Pakhtusova <em>et al.</em>, <a href="#bph13439-bib-0059" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0059">2003</a>). All experiments were performed in accordance with Institutional Animal Care and Use Committee guidelines and regulations at Pfizer Inc. (Groton, CT). Dispersed cells were placed in Ca<sup>2</sup><sup>+</sup> imaging buffer containing 129&nbsp;mM NaCl, 5&nbsp;mM NaHCO<sub>3</sub>, 4.7&nbsp;mM KCl, 1.2&nbsp;mM KH<sub>2</sub>PO<sub>4</sub>, 2&nbsp;mM CaCl<sub>2</sub>, 1.2&nbsp;mM MgSO<sub>4</sub>, and 10&nbsp;mM HEPES and pH adjusted to 7.4. Depending on the experiment, either 3 or 9&nbsp;mM glucose was added. For imaging, cells were loaded with the Ca<sup>2</sup><sup>+</sup>-sensitive fluorescent indicator, Fura-2AM for 35&nbsp;min at room temperature and perfused (1&ndash;2&nbsp;mL&sdot;min<sup>&minus;1</sup>) with imaging buffer (35&deg;C) for at least 5&nbsp;min prior to imaging. Cells were excited at wavelengths of 340 and 380&nbsp;nm every 5&ndash;8&nbsp;s, and emission values were detected above 510&nbsp;nm. A single concentration of PF-05190457 or Compound <b>2</b> (1&nbsp;&times;&nbsp;10<sup>&ndash;10</sup>&nbsp;&minus;&nbsp;1&nbsp;&times;&nbsp;10<sup>&ndash;6</sup>&nbsp;M) was applied until the calcium response plateaued (5&ndash;15&nbsp;min) followed by a washout until the calcium response returned to baseline prior to the addition of the sulphonylurea glibenclamide (100&nbsp;&mu;M). In all experiments, a concentration of 9&nbsp;mM glucose imaging buffer was used except when testing the glucose dependence of PF-05190457. In these experimental runs, 3&nbsp;mM glucose Ca<sup>2</sup><sup>+</sup> imaging buffer was used. To test the additive effects of PF-05190457 and glucagon-like peptide-1 (GLP-1), the EC<sub>50</sub> of each were combined and administered at the same time in the perfusion system to the cells (Moens <em>et al</em>., <a href="#bph13439-bib-0053" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0053">1996</a>). An average trace was generated per experiment, and the initial baseline value was recorded and compared with the peak response of PF-05190457 as well as to the peak response of glibenclamide. The average compound response was then reported as a percentage of the glibenclamide response. Normalized data from all experiments were averaged and plotted as a concentration&ndash;response curve (<em>n</em>&nbsp;=&nbsp;3 rats statistically relevant for a 10-point concentration&ndash;response curve), which was fit using the log [agonist] versus response function within <span class="smallCaps">g</span>raphpad <span class="smallCaps">p</span>rism to generate an EC<sub>50</sub>. Data are expressed as mean&nbsp;&plusmn;&nbsp;SEM.</p></div></div><div class="section" id="bph13439-sec-0012"><h4>Data and statistical analysis</h4><div class="para"><p>The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis <em>et al.</em>, <a href="#bph13439-bib-0022" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0022">2015</a>). To assess the uncertainty associated with the estimates of association rate constant and time to achieve equilibrium, the Delta method was applied to approximate the standard errors of on-rate and time to achieve equilibrium using the estimates of binding kinetic parameters and their standard errors based on the direct [<sup>3</sup>H]-PF-05190457 and indirect Motulsky modelling implemented in NONMEM version V (University of California at San Francisco, CA).</p></div><div class="para"><p>A paired <em>t</em>-test was used to determine the significance of the effect of PF-05190457 on vagal afferent firing (two tailed). One-way ANOVA was applied to analyse the change in intracellular Ca<sup>2</sup><sup>+</sup> in rat dispersed islets to determine whether PF-05190457 has an additive effect with GLP-1 on intracellular Ca<sup>2</sup><sup>+</sup> and peak calcium response (%) to test whether the co-administration of an EC<sub>50</sub> of PF-05190457 (10&nbsp;nM) and EC<sub>50</sub> of GLP-1 will result in a maximal increase in intracellular Ca<sup>2</sup><sup>+</sup>, where the two-sided <em>P</em>-values adjusted by the Dunnett's test were provided. <em>P</em>&nbsp;&lt;&nbsp;0.05 was used as the level of probability deemed to constitute the threshold for statistical significance when comparing groups.</p></div></div></div><div class="section" id="bph13439-sec-0013"><div class="headingCont"><h3>Results</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><div class="section" id="bph13439-sec-0014"><h4>PF-05190457 is a potent ghrelin receptor ligand across species</h4><div class="para"><p>The binding kinetics of PF-05190457 where approximated in the radioligand filter assay by determining <em>K</em><sub>i</sub> values after a 90&nbsp;min and 24&nbsp;h incubation. Potency was similar over time with a <em>K</em><sub>i</sub> of 2.49&nbsp;nM CI 2.18&ndash;2.85&nbsp;nM at 90&nbsp;min versus 1.42&nbsp;nM CI 1.21&ndash;1.6&nbsp;nM at 24&nbsp;h (Figure&nbsp;<a href="#bph13439-fig-0001" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0001">1</a>A). The human potency for PF-05190457 was comparable using SPA (<em>K</em><sub>i</sub> 4.4&nbsp;nM CI 2.1&ndash;9.1&nbsp;nM, <em>n</em>&nbsp;=&nbsp;10) and no species difference was detected (dog 3.6&nbsp;nM CI 2.9&ndash;4.4&nbsp;nM, <em>n</em>&nbsp;=&nbsp;9; primate 1.8&nbsp;nM CI 1.6&ndash;2.2&nbsp;nM, <em>n</em>&nbsp;=&nbsp;8; rat 3.2&nbsp;nM C.I. 2.8&ndash;3.6, <em>n</em>&nbsp;=&nbsp;49 and mouse 7.7&nbsp;nM C.I. 5.9&ndash;10.1&nbsp;nM, <em>n</em>&nbsp;=&nbsp;15; Figure&nbsp;<a href="#bph13439-fig-0001" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0001">1</a>B). To determine PF-05190457 <em>K</em><sub>on</sub> and <em>K</em><sub>off</sub>, a quantitative Motulsky and Mahan indirect method was applied (Motulsky and Mahan, <a href="#bph13439-bib-0055" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0055">1984</a>). PF-05190457 had an estimated <em>K</em><sub>on</sub> of 109275&nbsp;M<sup>&minus;1</sup>*s<sup>&minus;1</sup>, <em>K</em><sub>off</sub> of 0.000628&nbsp;s<sup>&minus;1</sup> (Table&nbsp;<a href="#bph13439-tbl-0001" class="tableLink" title="Link to table" rel="references:#bph13439-tbl-0001">1A</a>) and required 1.2&nbsp;h to achieve equilibrium (Figure&nbsp;<a href="#bph13439-fig-0001" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0001">1</a>C). The human <em>K</em><sub>d</sub> for PF-05190457 at equilibrium was 5.75&nbsp;nM (<em>n</em>&nbsp;=&nbsp;8). PF-0590457 was also radiolabelled to evaluate direct receptor kinetics. [<sup>3</sup>H]PF-05190457 had an estimated <em>K</em><sub>on</sub> of 65534&nbsp;M<sup>&minus;1</sup>*s<sup>&minus;1</sup>, <em>K</em><sub>off</sub> of 0.0002&nbsp;s<sup>&minus;1</sup> (Table&nbsp;<a href="#bph13439-tbl-0002" class="tableLink" title="Link to table" rel="references:#bph13439-tbl-0002">1B</a>) and required 3.8&nbsp;h to achieve equilibrium (Figure&nbsp;<a href="#bph13439-fig-0001" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0001">1</a>D). The human <em>K</em><sub>d</sub> for [<sup>3</sup>H]-PF-05190457 was 3.09&nbsp;nM (<em>n</em>&nbsp;=&nbsp;7).</p></div><div id="bph13439-fig-0001" class="figure"><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/image_n/bph13439-fig-0001.png?v=1&amp;t=ionz6pyv&amp;s=59b8c26ed2b057744e806ab74127746c24688ea4"><img id="bph13439-fig-0001_img" alt="image" src="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/image_t/bph13439-fig-0001-t.gif?v=1&amp;t=ionz6pyw&amp;s=0e62e64ef4b2013519b6bd6eaeea08d0f0581096" class="fc-figure-img" /></a><div class="caption" id="bph13439-fig-0001_caption"><p><span class="label">Figure&nbsp;1. </span>(A) The <em>in vitro</em> potency of PF-05190457 against the human ghrelin receptor using filter binding at 90&thinsp;min and 24&thinsp;h. The concentration&ndash;response curves represent the average &plusmn; SD for % inhibition at each concentration tested where <em>n</em>&thinsp;=&thinsp;86&ndash;103 replicates over 52 (90&thinsp;min) or 44 experiments (24&thinsp;h). (B) The quantitative association and dissociation kinetics of PF-05190457 using [<sup>125</sup>I]ghrelin binding to human ghrelin receptor membranes in the presence or absence of 1, 10 or 100&thinsp;nM PF-05190457. The specific binding plot represents the arithmetic mean &plusmn; SEM at each time point tested over eight experiments. (C) The <em>in vitro</em> potency of PF-051907457 against the ghrelin receptor across species. The concentration&ndash;response curves represent the mean &plusmn; SD for the % inhibitation values at each concentration tested where <em>n</em>&thinsp;=&thinsp;16&ndash;103 replicates over 52 (human), 9 (dog), 8 (primate), 49 (rat) or 15 experiments (mouse). (D) The association and dissociation kinetics of [<sup>3</sup>H]PF-05190457 a (3 and 10&thinsp;nM) over 7&thinsp;h. Each specific binding point represents the arithmetic mean &plusmn; SEM at each time point tested over seven experiments.</p><p class="downloadToPowerpoint"><a href="/doi/10.1111/bph.13439/figure.pptx?figureAssetHref=image_n/bph13439-fig-0001.png">Download figure to PowerPoint</a></p></div></div><div class="table" id="bph13439-tbl-0001"><table class="topbotR"><caption><span class="tTitle"><span class="label">Table&nbsp;1A.&nbsp;</span>Indirect quantitative (Motulsky and Mahan) method parameter summary of PF-05190457</span></caption><thead class="vBottom"><tr class="none"><th colspan="4" class="hLeft" rowspan="1">Table 1A Indirect method (Motulsky and Mahan)</th></tr><tr class="none"><th class="hLeft" rowspan="1" colspan="1">Parameter</th><th class="hChar" rowspan="1" colspan="1">Estimate</th><th class="hCenter" rowspan="1" colspan="1">IOV (CV%)</th><th class="hCenter" rowspan="1" colspan="1">RSE (CV%)</th></tr></thead><tfoot><tr><td colspan="4" rowspan="1"><div class="noteGroup" id="bph13439-ntgp-0001"><ul id="footnotes" class="noteGroup custom"><li id="bph13439-note-0001"><span class="bullet"><sup><i></i></sup></span><div class="text"><p>Data represent mean, interocassion variability (IOV), and relative standard error (RSE). Maximum binding (<em>B</em><sub>max</sub>), tracer equilibrium dissociation constant (<em>K</em><sub>d</sub><em>L</em>), tracer dissociation rate constant (<em>K</em><sub>off</sub><em>L</em>), tracer association rate constant (<em>K</em><sub>on</sub><em>L</em>), drug equilibrium dissociation constant (<em>K</em><sub>d</sub><em>D</em>), drug dissociation rate constant (<em>K</em><sub>off</sub><em>D</em>), drug association rate constant (<em>K</em><sub>on</sub><em>D</em>) estimates are summarized in this table. <em>B</em><sub>max</sub> was estimated for each experiment (<em>n</em>&nbsp;=&nbsp;9 experiments). <em>K</em><sub>d</sub><em>L</em> was estimated separately.</p></div></li><li id="bph13439-note-0002"><span class="bullet">*</span><div class="text"><p> median estimate</p></div></li><li id="bph13439-note-0003"><span class="bullet">**</span><div class="text"><p> posthoc calculation</p></div></li></ul></div></td></tr></tfoot><tbody class="vTop"><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><em>B</em><sub>max</sub> (M)</td><td class="hChar" rowspan="1" colspan="1">1.21E-11<a href="#bph13439-note-0002" class="noteLink" title="Link to note" rel="references:#bph13439-note-0002">*</a></td><td class="hChar" rowspan="1" colspan="1">108.0<a href="#bph13439-note-0003" class="noteLink" title="Link to note" rel="references:#bph13439-note-0003">**</a></td><td class="hChar" rowspan="1" colspan="1">7.2</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><em>K</em><sub>d</sub><em>L</em> (M)</td><td class="hChar" rowspan="1" colspan="1">1.23E-10, fixed<a href="#bph13439-note-0002" class="noteLink" title="Link to note" rel="references:#bph13439-note-0002">*</a></td><td class="hChar" rowspan="1" colspan="1">37.0, fixed</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><em>K</em><sub>off</sub><em>L</em> (s<sup>&minus;1</sup>)</td><td class="hChar" rowspan="1" colspan="1">0.0013</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td><td class="hChar" rowspan="1" colspan="1">9.1</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><em>K</em><sub>off</sub><em>D</em>, PF-05190457 (s<sup>&minus;1</sup>)</td><td class="hChar" rowspan="1" colspan="1">0.000628</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td><td class="hChar" rowspan="1" colspan="1">14.4</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><em>K</em><sub>d</sub><em>D</em>, PF-05190457 (M)</td><td class="hChar" rowspan="1" colspan="1">5.75E-09</td><td class="hChar" rowspan="1" colspan="1">30.9</td><td class="hChar" rowspan="1" colspan="1">12.0</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><em>K</em><sub>on</sub><em>D</em>, PF-05190457 (M<sup>&minus;1</sup>&nbsp;s<sup>&minus;1</sup>)</td><td class="hChar" rowspan="1" colspan="1">109275</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td><td class="hChar" rowspan="1" colspan="1">10.7</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1">Equilibrum time (s)</td><td class="hChar" rowspan="1" colspan="1">4423</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1">Additive residual error</td><td class="hChar" rowspan="1" colspan="1">0.1, fixed</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1">Proportional residual error (CV%)</td><td class="hChar" rowspan="1" colspan="1">33</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td></tr></tbody></table></div><div class="table" id="bph13439-tbl-0002"><table class="topbotR"><caption><span class="tTitle"><span class="label">Table&nbsp;1B.&nbsp;</span>Direct quantitative method parameter summary of PF-05190457</span></caption><thead class="vBottom"><tr class="none"><th colspan="4" class="hLeft" rowspan="1">Table 1B Direct method</th></tr><tr class="none"><th class="hLeft" rowspan="1" colspan="1">Parameter</th><th class="hCenter" rowspan="1" colspan="1">Estimate</th><th class="hCenter" rowspan="1" colspan="1">IOV (CV%)</th><th class="hCenter" rowspan="1" colspan="1">RSE (CV%)</th></tr></thead><tfoot><tr><td colspan="4" rowspan="1"><div class="noteGroup" id="bph13439-ntgp-0002"><ol id="footnotes" class="noteGroup custom"><li id="bph13439-note-0004"><span class="bullet"><sup><i></i></sup></span><div class="text"><p>Data represent mean, interocassion variability (IOV) and relative standard error (RSE). Maximum binding (<em>B</em><sub>max</sub>), drug equilibrium dissociation constant (<em>K</em><sub>d</sub><em>D</em>), drug dissociation rate constant (<em>K</em><sub>off</sub><em>D</em>), drug association rate constant (<em>K</em><sub>on</sub><em>D</em>) estimates are summarized in this table.</p></div></li></ol></div></td></tr></tfoot><tbody class="vTop"><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><em>B</em><sub>max</sub> &ndash; Study (M)</td><td class="hCenter" rowspan="1" colspan="1">7.12E-10</td><td class="hCenter" rowspan="1" colspan="1">&mdash;</td><td class="hChar" rowspan="1" colspan="1">2.0</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><em>K</em><sub>off</sub><em>D</em>, PF-05190457 (s<sup>&minus;1</sup>)</td><td class="hCenter" rowspan="1" colspan="1">0.0002</td><td class="hCenter" rowspan="1" colspan="1">&mdash;</td><td class="hChar" rowspan="1" colspan="1">4.7</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><em>K</em><sub>d</sub><em>D</em>, PF-05190457 (M)</td><td class="hCenter" rowspan="1" colspan="1">3.09E-9</td><td class="hCenter" rowspan="1" colspan="1">&mdash;</td><td class="hChar" rowspan="1" colspan="1">3.9</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1"><em>K</em><sub>on</sub><em>D</em>, PF-05190457 (M<sup>&minus;1</sup>&nbsp;s<sup>&minus;1</sup>)</td><td class="hCenter" rowspan="1" colspan="1">65534</td><td class="hCenter" rowspan="1" colspan="1">&mdash;</td><td class="hChar" rowspan="1" colspan="1">4.3</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1">Equilibrium time (s)</td><td class="hCenter" rowspan="1" colspan="1">13689</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1">Additive residual error (CV%)</td><td class="hCenter" rowspan="1" colspan="1">0, fixed</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1">Proportional residual error for saturation binding data (CV%)</td><td class="hCenter" rowspan="1" colspan="1">5</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td></tr><tr class="none"><td class="hLeft" rowspan="1" colspan="1">Proportional residual error for association data (CV%)</td><td class="hCenter" rowspan="1" colspan="1">4</td><td class="hCenter" rowspan="1" colspan="1">&nbsp;</td><td class="hChar" rowspan="1" colspan="1">&nbsp;</td></tr></tbody></table></div></div><div class="section" id="bph13439-sec-0015"><h4>PF-05190457 is a competitive antagonist with inverse agonist activity</h4><div class="para"><p>To evaluate functional activity, PF-05190457 was profiled as an agonist, inverse agonist and as an antagonist. As shown in Figure&nbsp;<a href="#bph13439-fig-0002" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0002">2</a>A, the concentration&ndash;response curve generated in the agonist mode produced a decreasing curve that dipped below the 0% effect line (basal activity), indicating inverse agonist activity (IC<sub>50</sub> 4.9&nbsp;nM CI 3.5&ndash;6.7&nbsp;nM, <em>n</em>&nbsp;=&nbsp;16). PF-05190457 also antagonized ghrelin-stimulated changes with a <em>K</em><sub>i</sub> 6.6&nbsp;nM C.I. 5&ndash;8.6&nbsp;nM (<em>n</em>&nbsp;=&nbsp;16; Figure&nbsp;<a href="#bph13439-fig-0002" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0002">2</a>B). PF-05190457 was a potent competitive antagonist with a slope of 0.9&nbsp;&plusmn;&nbsp;0.1 and a <em>K</em><sub>b</sub> of 1.8&nbsp;&plusmn;&nbsp;0.2&nbsp;nM, <em>n</em>&nbsp;=&nbsp;10 (Figure&nbsp;<a href="#bph13439-fig-0002" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0002">2</a>C).</p></div><div id="bph13439-fig-0002" class="figure"><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/image_n/bph13439-fig-0002.png?v=1&amp;t=ionz6pz9&amp;s=c856df8e709b680083bfe444c1ff2233cdac1ebc"><img id="bph13439-fig-0002_img" alt="image" src="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/image_t/bph13439-fig-0002-t.gif?v=1&amp;t=ionz6pza&amp;s=5ade55a75f23069d4797daaf52a32746eb7ab011" class="fc-figure-img" /></a><div class="caption" id="bph13439-fig-0002_caption"><p><span class="label">Figure&nbsp;2. </span>(A) The <em>in vitro</em> functional activity of PF-05190457 against the human ghrelin receptor as measured by europium-labelled guanosine-5&prime;-triphosphate (Eu-GTP). The agonist mode measured the ability of PF-05190457 to act as an agonist, partial agonist or inverse agonist receptor, and the observed negative % effect values were characteristic of an inverse agonist. The antagonist mode measured the ability of increasing concentrations of PF-05190457 to block ghrelin-stimulated changes (B). The concentration&ndash;response plot is a representative experiment from <em>n</em>&nbsp;=&nbsp;16 with 1&ndash;2 replicates per concentration and plotted as the mean % effect&nbsp;&plusmn;&nbsp;SD. (C) is the <em>K</em><sub>b</sub> potency of PF-05190457. Data represent the mean&nbsp;&plusmn;&nbsp;SEM at each concentration of PF-05190457 tested. Concentration ratio&nbsp;=&nbsp;EC<sub>50</sub> of ghrelin with PF-05190457/EC<sub>50</sub> of ghrelin without PF-05190457 (<em>n</em>&nbsp;=&nbsp;10 experiments).</p><p class="downloadToPowerpoint"><a href="/doi/10.1111/bph.13439/figure.pptx?figureAssetHref=image_n/bph13439-fig-0002.png">Download figure to PowerPoint</a></p></div></div></div><div class="section" id="bph13439-sec-0016"><h4>PF-05190457 increases gastric vagal afferent firing in rat <em>ex vivo</em></h4><div class="para"><p>Ghrelin has been shown to increase food intake via the gastric vagal afferents <em>in vivo</em>, an effect that is abolished in rats with gastric vagotomy (Date <em>et al.</em>, <a href="#bph13439-bib-0026" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0026">2002</a>). In addition, ghrelin inhibits neuronal firing of mouse vagal afferent nerve fibres <em>ex vivo</em> (Page <em>et al.</em>, <a href="#bph13439-bib-0057" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0057">2007</a>) and in rats (Supporting Information Figure 3S). The effects of PF-05190457 on gastric vagal nerve activity were assessed through electrophysiological recordings of gastric afferent nerve activity in a rat <em>ex vivo</em> stomach/vagal preparation. Intragastric arterial administration of PF-05190457 elicited a concentration-dependent increase in gastric afferent vagal nerve activity (baseline 9.2&nbsp;&plusmn;&nbsp;2.1&nbsp;Hz; PF-05190457 <em>E</em><sub>max</sub> 16.8&nbsp;&plusmn;&nbsp;4.8&nbsp;Hz; <em>n</em>&nbsp;=&nbsp;5; <em>P</em>&nbsp;&lt;&nbsp;0.05) with an EC<sub>50</sub> of 10.7&nbsp;&plusmn;&nbsp;0.5&nbsp;nM (Figure&nbsp;<a href="#bph13439-fig-0003" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0003">3</a>A and B). The neutral antagonist Compound <b>2</b> with no inverse agonism also elicited a concentration-dependent increase in vagal firing (<em>n</em>&nbsp;=&nbsp;4; Figure&nbsp;<a href="#bph13439-fig-0003" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0003">3</a>C).</p></div><div id="bph13439-fig-0003" class="figure"><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/image_n/bph13439-fig-0003.png?v=1&amp;t=ionz6pze&amp;s=0db88bd47a1dad66f0657e2a2bc4987257e92762"><img id="bph13439-fig-0003_img" alt="image" src="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/image_t/bph13439-fig-0003-t.gif?v=1&amp;t=ionz6pze&amp;s=2397624bf765bce684f5bc5b208057ec443ba124" class="fc-figure-img" /></a><div class="caption" id="bph13439-fig-0003_caption"><p><span class="label">Figure&nbsp;3. </span>(A) <span class="sans-serif ">An example trace of PF-05190457</span> <span class="sans-serif ">E</span><sub><span class="sans-serif ">max</span></sub> 10<sup>&minus;6</sup>&nbsp;<span class="sans-serif ">M increasing vagal afferent firing.</span> (B) and (C) Concentration&ndash;response curves of PF-05190457 and compound <b>2</b> respectively, on rat gastric vagal afferent firing <em>ex vivo</em>. Data represent mean&nbsp;&plusmn;&nbsp;SEM (PF-05190457 0.1&ndash;1&nbsp;nM <em>n</em>&nbsp;=&nbsp;4; 10&ndash;1000&nbsp;nM <em>n</em>&nbsp;=&nbsp;5; compound <b>2</b> <em>n</em>&nbsp;=&nbsp;4).</p><p class="downloadToPowerpoint"><a href="/doi/10.1111/bph.13439/figure.pptx?figureAssetHref=image_n/bph13439-fig-0003.png">Download figure to PowerPoint</a></p></div></div></div><div class="section" id="bph13439-sec-0017"><h4>PF-05190457 increases intracellular Ca<sup>2+</sup> in rat dispersed islets <em>ex vivo</em></h4><div class="para"><p>As ghrelin receptors are expressed locally within the pancreatic islet and ghrelin inhibits intracellular Ca<sup>2</sup><sup>+</sup> within single cells (Gnanapavan <em>et al.</em>, <a href="#bph13439-bib-0036" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0036">2002</a>; Volante <em>et al.</em>, <a href="#bph13439-bib-0085" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0085">2002</a>; Wierup <em>et al.</em>, <a href="#bph13439-bib-0088" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0088">2002</a>; Kageyama <em>et al.</em>, <a href="#bph13439-bib-0043" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0043">2005</a>; Wierup and Sundler, <a href="#bph13439-bib-0089" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0089">2005</a>; Dezaki <em>et al.</em>, <a href="#bph13439-bib-0030" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0030">2007</a>; Damdindorj <em>et al</em>., <a href="#bph13439-bib-0023" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0023">2012</a>), changes in intracellular Ca<sup>2</sup><sup>+</sup> in rat dispersed islets <em>ex vivo</em> after treatment with PF-05190457 were measured to (i) assess intracellular Ca<sup>2</sup><sup>+</sup> increases in the presence of 3&nbsp;mM (low) and 9&nbsp;mM (high) glucose; (ii) evaluate the <em>ex vivo</em> potency of PF-05190457 on intracellular Ca<sup>2</sup><sup>+</sup>; and (iii) determine whether PF-05190457 has an additive effect with GLP-1 on intracellular Ca<sup>2</sup><sup>+</sup>. A high concentration of PF-05190457 (100&nbsp;nM) failed to evoke a change in intracellular Ca<sup>2</sup><sup>+</sup> in the presence of 3&nbsp;mM glucose but evoked a maximal increase in intracellular Ca<sup>2</sup><sup>+</sup> in 9&nbsp;mM glucose (Figure&nbsp;<a href="#bph13439-fig-0004" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0004">4</a>A), which was comparable with the insulin secretagogue glibenclamide (100&nbsp;nM), confirming efficacy and glucose dependence of PF-05190457 (<em>n</em>&nbsp;=&nbsp;4; Figure&nbsp;<a href="#bph13439-fig-0004" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0004">4</a>C). In contrast, the neutral antagonist Compound <b>2</b> which lacks inverse agonism had no effect (<em>n</em>&nbsp;=&nbsp;3; Figure&nbsp;<a href="#bph13439-fig-0004" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0004">4</a>B and D). PF-05190457 induced a concentration-dependent increase in intracellular Ca<sup>2</sup><sup>+</sup> in 9&nbsp;mM glucose with an EC<sub>50</sub> 9.3&nbsp;&plusmn;&nbsp;1&nbsp;nM, <em>n</em>&nbsp;=&nbsp;3&ndash;7 (Figure&nbsp;<a href="#bph13439-fig-0004" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0004">4</a>E). In contrast to Compound <b>2</b> which had no effect, co-administration of an EC<sub>50</sub> of PF-05190457 (10&nbsp;nM) and EC<sub>50</sub> of GLP-1 (1&nbsp;nM; Moens <em>et al.</em>, <a href="#bph13439-bib-0053" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0053">1996</a>) resulted in a maximal increase in intracellular Ca<sup>2</sup><sup>+</sup> (<em>n</em>&nbsp;=&nbsp;6; <em>P</em>&nbsp;&lt;&nbsp;0.05; Figure&nbsp;<a href="#bph13439-fig-0004" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0004">4</a>F).</p></div><div id="bph13439-fig-0004" class="figure"><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/image_n/bph13439-fig-0004.png?v=1&amp;t=ionz6pzk&amp;s=1edf464a344401e086427c6c8ab6bf3cb07628f2"><img id="bph13439-fig-0004_img" alt="image" src="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/image_t/bph13439-fig-0004-t.gif?v=1&amp;t=ionz6pzl&amp;s=e557057e4a152b2a3bf5f67ff046a9d007e53a7d" class="fc-figure-img" /></a><div class="caption" id="bph13439-fig-0004_caption"><p><span class="label">Figure&nbsp;4. </span>(A) Example raw trace of PF-5109457 (1&nbsp;&times;&nbsp;10<sup>&ndash;7</sup>&nbsp;M) in the presence of 9&nbsp;mM glucose on intracellular Ca<sup>2</sup><sup>+</sup> in rat dispersed islets (A: 9&nbsp;mM glucose buffer baseline; B: 1&nbsp;&times;&nbsp;10<sup>&ndash;7</sup>&nbsp;M PF-05190457 in 9&nbsp;mM glucose buffer; C: 9&nbsp;mM glucose buffer wash; D: unrecorded wash to prevent bleaching and E: 1&nbsp;&times;&nbsp;10<sup>&ndash;7</sup>&nbsp;M Glibenclamide in 9&nbsp;mM glucose wash). (B) The same as (A) but with compound <b>2</b>. (C) The average glucose-dependent effect of PF-05190457 on intracellular Ca<sup>2</sup><sup>+</sup> in rat dispersed islets in the presence of 3 and 9&nbsp;mM glucose. All data are normalized against the positive control glibenclamide. Data represent the mean&nbsp;&plusmn;&nbsp;SEM (<em>n</em>&nbsp;=&nbsp;4). Comparison of compound <b>2</b> to glibenclamide in the presence of 9&nbsp;mM glucose (<em>n</em>&nbsp;=&nbsp;3; D). Concentration&ndash;response curve of PF-05190457 showing the mean&nbsp;&plusmn;&nbsp;SEM, where <em>n</em>&nbsp;=&nbsp;3&ndash;7 pending concentration (E). (F) Additive effect of GLP-1 EC<sub>50</sub> and PF-05190457 IC<sub>50</sub> on intracellular calcium in rat dispersed islets in the presence of 9&nbsp;mM glucose. All data are normalized against glibenclamide. Data represent the mean&nbsp;&plusmn;&nbsp;SEM (<em>n</em>&nbsp;=&nbsp;6; ***<em>P</em>&nbsp;&lt;&nbsp;0.05 two-tailed <em>t</em>-test with Dunnett adjustment).</p><p class="downloadToPowerpoint"><a href="/doi/10.1111/bph.13439/figure.pptx?figureAssetHref=image_n/bph13439-fig-0004.png">Download figure to PowerPoint</a></p></div></div></div></div><div class="section" id="bph13439-sec-0018"><div class="headingCont"><h3>Discussion</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><div class="para"><p>Here, we report a novel potent small-molecule ghrelin receptor competitive antagonist that has (i) equipotent inverse agonism activity; (ii) moderately fast on and fast off kinetics requiring 4&nbsp;h to achieve equilibrium; (iii) increases rat vagal afferent firing <em>ex vivo</em>, (iv) increases intracellular calcium in rat dispersed islets that is comparable with sulphonylureas but in a glucose-dependent manner; and (v) has the potential to have additive efficacy on top of approved GLP-1 receptor agonist therapy.</p></div><div class="para"><p>Since the discovery of ghrelin, various functions of ghrelin, including growth hormone release, gastric acid secretion, gastrointestinal motility, feeding behaviour, glucose metabolism, memory and also antidepressant effects, have been studied (Sakata and Sakai, <a href="#bph13439-bib-0074" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0074">2010</a>). Since the first reports of ghrelin as the only peripheral hunger-stimulating hormone more than a decade ago, much attention has been focused on developing a novel antagonist approach to treat obesity and more recently improve insulin secretion and insulin sensitivity in humans (Broglio <em>et al.</em>, <a href="#bph13439-bib-0009" class="referenceLink" title="Link to bibliographic citations" rel="references:#bph13439-bib-0009 #bph13439-bib-0010 #bph13439-bib-0011 #bph13439-bib-0012 #bph13439-bib-0013">2001, 2002, 2003a, 2003b, 2004</a>; Arosia <em>et al.</em>, <a href="#bph13439-bib-0002" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0002">2003</a>; Reimer <em>et al.</em>, <a href="#bph13439-bib-0067" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0067">2003</a>; Dezaki <em>et al.</em>, <a href="#bph13439-bib-0029" class="referenceLink" title="Link to bibliographic citations" rel="references:#bph13439-bib-0029 #bph13439-bib-0030">2004, 2007</a>; Gauna <em>et al</em>., <a href="#bph13439-bib-0035" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0035">2004</a>; Lucidi <em>et al.</em>, <a href="#bph13439-bib-0049" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0049">2005</a>; Damjanovic <em>et al.</em>, <a href="#bph13439-bib-0024" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0024">2006</a>; Sun <em>et al.</em>, <a href="#bph13439-bib-0078" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0078">2006</a>; Vestergaard <em>et al.</em>, <a href="#bph13439-bib-0082" class="referenceLink" title="Link to bibliographic citations" rel="references:#bph13439-bib-0082 #bph13439-bib-0083 #bph13439-bib-0084">2007, 2008a, 2008b</a>; Tong <em>et al.</em>, <a href="#bph13439-bib-0080" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0080">2010</a>). Unfortunately, the field has been hampered due to lack of non-peptidic antagonists, poor potency, lack of selectivity, limited efficacy and toleration issues which have ultimately prevented testing the hypothesis in humans (Schellekens <em>et al.</em>, <a href="#bph13439-bib-0077" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0077">2010</a>). As a consequence, there has been a demand for novel strategic approaches to ensure a deeper understanding of the pharmacology of ghrelin receptor antagonists underlying ghrelin-mediated pathways controlling energy homeostasis and insulin secretion necessary for a unique therapeutic intervention.</p></div><div class="para"><p>PF-05190457 is the first ghrelin receptor antagonist to advance into human clinical studies (NCT01247896). PF-05190457 is approximately 10-fold more potent than previously identified small-molecule antagonists (Perdon&agrave; <em>et al.</em>, <a href="#bph13439-bib-0065" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0065">2011</a>; Mihalic <em>et al.</em>, <a href="#bph13439-bib-0052" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0052">2012</a>; Moulin <em>et al.</em>, <a href="#bph13439-bib-0056" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0056">2013</a>; Cameron <em>et al.</em>, <a href="#bph13439-bib-0017" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0017">2014</a>), and also has greater than 100-fold potency and selectivity compared with peptide antagonists. To date, little attention has been spent looking at the kinetics of peptide or non-peptide ghrelin receptor antagonists to optimize the potency and temporal requirements for efficacy studies. Perdon&agrave; <em>et al.</em> (<a href="#bph13439-bib-0065" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0065">2011</a> revealed that GSK1614343 and YIL-781 showed higher potency in FLIPR assays than in [<sup>3</sup>H]-IP assays suggesting the hemi-equilibria conditions were not optimal to determine compound behaviour or potency. Likewise, [<span class="smallCaps">d</span>-Arg1,<span class="smallCaps">d</span>-Phe5,<span class="smallCaps">d</span>-Trp7,9,Leu11]-substance P is reported to be &lt;100-fold more potent as an inverse agonist than as an antagonist, yet the temporal conditions of the assays were not reported (Holst <em>et al.</em>, <a href="#bph13439-bib-0039" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0039">2003</a>). The present study addresses for the first time ghrelin receptor antagonist kinetics. A good correlation was observed between the Motulsky and Mahan methodology and direct radiolabelling of PF-05190457 which highlighted PF-05190457 as a moderately fast on and fast off ligand that requires 4&nbsp;h to achieve equilibrium. To compare kinetics, the D<sub>2</sub> receptor antagonists have been most studied and provide the most diverse range in <em>K</em><sub>on</sub> and <em>K</em><sub>off</sub> reported. The receptor kinetics of D<sub>2</sub> receptor antagonist antipsychotic drugs are well studied and range from 3.3E<sup>&minus;5</sup> to 5E<sup>&minus;</sup><sup>2</sup>&nbsp;s<sup>&minus;1</sup> in <em>K</em><sub>off</sub>, and 1.8E<sup>8</sup> to 2.8E<sup>9</sup>&nbsp;M<sup>&minus;1</sup>&nbsp;s<sup>&minus;1</sup> in <em>K</em><sub>on</sub> (Kapur and Seeman, <a href="#bph13439-bib-0045" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0045">2000</a>). Their binding affinity and the functional activity has been shown to correlate with <em>K</em><sub>off</sub>, highlighting the importance of this measure. Compared with mid-range binding affinity antipsychotic drugs (sertindole, chlorpromazine and raclopride), PF-05190457 <em>K</em><sub>off</sub> is similar (within twofold), and <em>K</em><sub>on</sub> is ~20&nbsp;000-fold slower (Kapur and Seeman, <a href="#bph13439-bib-0045" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0045">2000</a>). PF-05190457 <em>K</em><sub>off</sub> at the ghrelin receptor is similar (within twofold) to risperidone, paliperidone, aripiprazole, ziprasidone and haloperidol; ~10-fold slower than olanzipine and dopamine; and ~100-fold slower than quetiapine, raclopride and IBZM at D<sub>2</sub> receptor (Richelson and Souder, <a href="#bph13439-bib-0068" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0068">2000</a>). PF-05190457 <em>K</em><sub>on</sub> at ghrelin receptor is approximately twofold slower compared with risperidone, paliperidone, aripiprazole, ziprasidone, haloperidol, olanzipine, dopamine, quetiapine, raclopride and IBZM at the D<sub>2</sub> receptor. A summary of PF-05190457 potency versus time for different assay conditions is provided in Figure&nbsp;<a href="#bph13439-fig-0005" class="figureLink" title="Link to figure" rel="references:#bph13439-fig-0005">5</a> and clearly shows how potency increases with longer incubation of PF-05190457 with the ghrelin receptor and plateaus once equilibrium has been achieved. This effect is important to consider when directly comparing and referring to concentration-dependent effects across a range of <em>in vitro</em> recombinant and <em>ex vivo</em> preparations which are limited by the temporal conditions necessary for each assay. A full understanding of receptor kinetics is also important when designing complex <em>in vivo</em> or clinical studies when full blockade of the receptor is required over acute or chronic efficacy studies in order to aid in the interpretation of pharmacokinetic/pharmacodynamic relationships and evaluation of adverse events.</p></div><div id="bph13439-fig-0005" class="figure"><a class="figZoom" title="Link to full-size figure" href="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/image_n/bph13439-fig-0005.png?v=1&amp;t=ionz6q91&amp;s=e7c36eabb5e1fd9032a8f1220dde53f1d28ccf9e"><img id="bph13439-fig-0005_img" alt="image" src="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/image_t/bph13439-fig-0005-t.gif?v=1&amp;t=ionz6q91&amp;s=0395dfea50d09f2619b44d10fec319084d93f29f" class="fc-figure-img" /></a><div class="caption" id="bph13439-fig-0005_caption"><p><span class="label">Figure&nbsp;5. </span><em>In vitro</em> and <em>ex vivo</em> potency of PF-05190457 across all assays against time. Good correlation in potency of PF-05190457 is observed using assays with the same exposure time, with an observed increase in potency with longer incubation times as equilibrium is achieved around 4&nbsp;h.</p><p class="downloadToPowerpoint"><a href="/doi/10.1111/bph.13439/figure.pptx?figureAssetHref=image_n/bph13439-fig-0005.png">Download figure to PowerPoint</a></p></div></div><div class="para"><p>The use of ghrelin receptor antagonists <em>in vivo</em> has been confusing to date; BIM28163 and GSK1614343 surprisingly increased food intake and body wt, whereas two chemically distinct small-molecule antagonists (compound 14f and YIL-781) decreased food intake (Halem <em>et al.</em>, <a href="#bph13439-bib-0038" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0038">2005</a>; Esler <em>et al.</em>, <a href="#bph13439-bib-0034" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0034">2007</a>; Costantini <em>et al.</em>, <a href="#bph13439-bib-0019" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0019">2011</a>; Puleo <em>et al.</em>, <a href="#bph13439-bib-0066" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0066">2012</a>). Whilst the pharmacokinetic properties and effects of central versus peripheral mechanism of actions is unknown, the dilemma raises many potential questions regarding the nature of the antagonist, such as (i) selectivity and off target pharmacology; (ii) does the neutral antagonist act like a partial agonist at the target sites of action depending on receptor densities; (iii) what functional cell-based screens should be used to elucidate the functional characteristics of the antagonist; and (iv) how would the ghrelin receptor antagonist behave at the site of action underlying ghrelin's orexigenic effects. The authors did a convincing job demonstrating that GSK1614343 effects are not driven by off target pharmacology as the increase in food intake and body wt were not observed in the ghrelin receptor knockout mouse. One notable difference between the antagonists that increased food intake versus those that decreased was the functional assay used to define the antagonist pharmacology. Agents that increased food intake were profiled by blocking ghrelin-induced increases in calcium. A Ca<sup>2</sup><sup>+</sup> mobilization assay has been traditionally used because the ghrelin-induced increases in growth hormone effects via the ghrelin receptor in the pituitary were shown to be G<sub>q</sub>-coupled. However, the ghrelin receptor underlying insulin secretion or food intake via the islet and vagus afferents are unlikely to be G<sub>q</sub> mediated. Studies by Dezaki <em>et al.</em> (<a href="#bph13439-bib-0030" class="referenceLink" title="Link to bibliographic citations" rel="references:#bph13439-bib-0030 #bph13439-bib-0032">2007, 2011</a>) and Damdindorj <em>et al.</em> (<a href="#bph13439-bib-0023" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0023">2012</a>) have shown that exogenous ghrelin stimulates a pertussis&ndash;toxin-sensitive pathway within rodent islets that attenuates cAMP-PKA signalling, activates Kv2.1 channels inhibiting glucose-dependent intracellular Ca<sup>2</sup><sup>+</sup> and insulin secretion. Peng <em>et al</em>. (<a href="#bph13439-bib-0064" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0064">2012</a>) also demonstrated that ghrelin inhibits insulin release by regulating the expression of inwardly rectifying potassium channel 6.2 in islets. Whilst the ghrelin signalling pathway within vagal afferent nerve terminals has not been reported and technically challenging due to neuronal viability with an overnight toxin treatment, ghrelin does modulate vagal afferent cell bodies excitability by activating K<sub>ATP</sub> conductance via a G<sub>&alpha;i</sub>-PI3K-Erk1/2-K<sub>ATP</sub> pathway (Grabauskas <em>et al.</em>, <a href="#bph13439-bib-0037" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0037">2015</a>). Other gastrointestinal anorexigenic agents known to excite gastric vagal afferents, for example, cholecystokinin (CCK), PYY<sub>3&ndash;36</sub>, GLP-1 and CB<sub>1</sub> receptor antagonists, are typically associated with increasing intracellular Ca<sup>2</sup><sup>+</sup> or cAMP for efficacy (<!--TODO: clickthrough URL--><a href="http://www.guidetopharmacology.org" title="Link to external resource: http://www.guidetopharmacology.org">http://www.guidetopharmacology.org</a>; Kakei <em>et al.</em>, <a href="#bph13439-bib-0044" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0044">2002</a>; Lankisch <em>et al.</em>, <a href="#bph13439-bib-0047" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0047">2002</a>; Burdyga <em>et al.</em>, <a href="#bph13439-bib-0015" class="referenceLink" title="Link to bibliographic citations" rel="references:#bph13439-bib-0015 #bph13439-bib-0016">2008, 2010</a>; Alexander <em>et al.</em>, <a href="#bph13439-bib-0002" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0002">2003</a>). Therefore, blocking elevations of intracellular Ca<sup>2</sup><sup>+</sup> via calcium entry into beta cells or vagal afferents would decrease insulin secretion and vagal afferent firing. The non-calcium mobilization assays such as forskolin-stimulated luciferase and [<sup>35</sup>S]-GTP&gamma;S used in identification of antagonists that decrease food intake may have identified alternative bias antagonists. Here, a non-traditional screening approach within the ghrelin receptor antagonist competitive space was applied. Using a non-biased GTP&gamma;S screen, the <em>in vitro</em> pharmacology was confirmed in putative native tissues underlying metabolic efficacy such as food intake and insulin secretion once potency, kinetics, selectivity, antagonism and inverse agonism was fully characterized. This approach simply builds the basic translation understanding of the pharmacology and mechanism of action prior to complex <em>in vivo</em> studies which have proved challenging to interpret alone.</p></div><div class="para"><p>Another potential difference to explain observed <em>in vivo</em> differences between antagonists may be whether the small molecules are solely neutral antagonists or also have inverse agonist properties. Because the ghrelin receptor has been shown <em>in vitro</em> to be constitutively active, it is debatable whether a ghrelin receptor inverse agonist or a neutral antagonist would be beneficial for obesity or metabolic disorders (Holst <em>et al.</em>, <a href="#bph13439-bib-0039" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0039">2003</a>). To date, the majority of nonpeptide compounds have claimed to be antagonists, with the exception of Pasternak <em>et al.</em> (<a href="#bph13439-bib-0060" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0060">2009</a>) who identified an inverse agonist with poor p.o. bioavailability (Rudolph <em>et al.</em>, <a href="#bph13439-bib-0071" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0071">2007</a>; Perdon&agrave; <em>et al.</em>, <a href="#bph13439-bib-0065" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0065">2011</a>; Sabbatini <em>et al.</em>, <a href="#bph13439-bib-0072" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0072">2011</a>; Mihalic <em>et al.</em>, <a href="#bph13439-bib-0052" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0052">2012</a>; Puleo <em>et al.</em>, <a href="#bph13439-bib-0066" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0066">2012</a>; Moulin <em>et al.</em>, <a href="#bph13439-bib-0056" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0056">2013</a>). PF-05190457 is an equipotent inverse agonist and neutral competitive antagonist working independently of ghrelin tone with the added advantage of not switching to a partial agonist.</p></div><div class="para"><p>Whilst the ghrelin receptor is constitutively active when used <em>in vitro</em> recombinant assays, the translation to inverse agonist activity in native tissues remains uncharacterized. In whole islets and perfused pancreas, a non-selective peptide ghrelin receptor antagonist and ghrelin anti-serum have been shown to increase intracellular glucose-dependent insulin secretion, suggesting an endogenous ghrelin tone (Egido <em>et al.</em>, <a href="#bph13439-bib-0033" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0033">2002</a>; Colombo <em>et al.</em>, <a href="#bph13439-bib-0018" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0018">2003</a>; Reimer <em>et al.</em>, <a href="#bph13439-bib-0067" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0067">2003</a>; Dezaki <em>et al.</em>, <a href="#bph13439-bib-0029" class="referenceLink" title="Link to bibliographic citations" rel="references:#bph13439-bib-0029 #bph13439-bib-0030 #bph13439-bib-0031">2004, 2007, 2008</a>). Here, we report that the ghrelin receptor in rat dispersed islet cells is constitutively active, as a minimal increase in intracellular calcium was observed with a neutral antagonist lacking inverse agonist activity, whereas in contrast PF-05190457 induced a profound increase that was equally efficacious to glibenclamide at pharmacologically relevant concentrations. Interestingly, the effect of PF-05190457 was glucose-dependent which is critical for a type 2 diabetes therapy to prevent complications of hypoglycaemia associated with glucose-independent treatments like sulphonylureas. The only glucose-dependent insulin secretagogues approved to date are GLP-1 receptor agonist analogues and dipeptidyl peptidase IV inhibitors that elevate endogenous GLP-1 levels. Despite superior efficacy, GLP-1 receptor agonists are considered third-line therapy because of dose limiting side effects (nausea) and their mode of administration (injectable). Interestingly, Damdindorj <em>et al.</em> (<a href="#bph13439-bib-0023" class="referenceLink" title="Link to bibliographic citation" rel="references:#bph13439-bib-0023">2012</a> has shown that ghrelin counteracts GLP-1 action to stimulate cAMP signalling and insulin secretion in islets. In support of these data, the present study shows for the first time that a ghrelin receptor inverse agonist can have an additive effect with GLP-1 receptor agonism and could therefore be used in combination with approved GLP-1 receptor agonists.</p></div><div class="para"><p>In summary, PF-05190457 is a novel potent ghrelin receptor competitive antagonist with inverse agonist activity <em>in vitro</em> that translates to putative native target tissues of interest involved in energy homeostasis and insulin secretion. The ghrelin receptor is constitutively active in dispersed islets and is the key receptor mediating the inhibitory effects of endogenous ghrelin secreted from the stomach on gastric vagal afferents to modulate gut brain neuronal signalling. PF-05190457 is a pharmacologically validated clinical candidate with potential to be a first in class treatment for excessive eating disorders, that is, Prader&ndash;Willi syndrome or type 2 diabetes, as a monotherapy or in combination with GLP-1.</p></div></div><div class="section" id="bph13439-sec-0019"><div class="headingCont"><h3>Acknowledgements</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><div class="para"><p>We would like to acknowledge Professor Gino Saccone (Flinders) and his laboratory for vagal afferent extracellular recording training and consultancy. We also acknowledge Jeffrey Koup, Pharm.D., A2PG consultancy for the indirect method analysis of PF-05190457 receptor kinetics.</p></div></div><div class="section" id="bph13439-sec-0020"><div class="headingCont"><h3>Author contributions</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><div class="para"><p>J.K. performed <em>in vitro</em> binding and functional experiments (Motulsky/Schild). J.C. was in-charge in disperse islet calcium imaging experiments. I.S. performed <em>in vitro</em> binding and functional experiments. P.L. participated in the design and interpretation of <em>in vitro</em> pharmacology. S.S. participated in vagal afferent firing experiments. C.V. performed Motulsky analysis and pharmacology temporal analysis. K.C., S.B. and K.M. participated in the design and synthesis of PF-05190457. K.L. participated in pharmadynamic and PF-05190457 free concentration study design. Y.Z. was the statistician on all <em>in vitro</em> and <em>ex vivo</em> assay design and analysis. M.J. participated in the design and interpretation of all <em>in vitro</em> and <em>ex vivo</em> studies.</p></div></div><div class="section" id="bph13439-sec-0076"><div class="headingCont"><h3>Conflict of interest</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><div class="para"><p>The authors declare no conflicts of interest.</p></div></div><div class="section" id="bph13439-sec-0075"><div class="headingCont"><h3>Declaration of transparency and scientific rigour</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><div class="para"><p>This <a href="http://onlinelibrary.wiley.com/doi/10.1111/bph.13405/abstract" rel="references:http://onlinelibrary.wiley.com/doi/10.1111/bph.13405/abstract">Declaration</a> acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research recommended by funding agencies, publishers and other organisations engaged with supporting research.</p></div></div><div id="bph13439-bibl-0001" class="bibliography"><div class="headingCont"><h3>References</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><ul class="plain"><li id="bph13439-bib-0001"><cite id="bph13439-cit-0002"><span class="author">Alexander SPH</span>, <span class="author">Davenport AP</span>, <span class="author">Kelly E</span>, <span class="author">Marrion N</span>, <span class="author">Peters JA</span>, <span class="author">Benson HE</span>, <em>et al.</em> (<span class="pubYear">2015</span>). <span class="articleTitle">The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors</span>. <span class="journalTitle">Br J Pharmacol</span> <span class="vol">172</span>: <span class="pageFirst">5744</span>&ndash;<span class="pageLast">5869</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1111/bph.13348/abstract">Abstract</a></li><li><a href="/doi/10.1111/bph.13348/full">Full Article (HTML)</a></li><li><a href="/doi/10.1111/bph.13348/epdf" class="readcubeEpdfLink">PDF(4444K)</a></li><li><a href="/doi/10.1111/bph.13348/pdf" class="readcubePdfLink">PDF(4444K)</a></li><li><a href="/doi/10.1111/bph.13348/references">References</a></li><li><a href="/resolve/reference/ISI?id=000366510500002">Web of Science&reg; Times Cited: 10</a></li></ul></div></li><li id="bph13439-bib-0002"><cite id="bph13439-cit-0003"><span class="author">Arosia M</span>, <span class="author">Ronchi CL</span>, <span class="author">Gebbia C</span>, <span class="author">Cappiello V</span>, <span class="author">Beck-Peccoz P</span>, <span class="author">Peracchi M</span> (<span class="pubYear">2003</span>). <span class="articleTitle">Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">88</span>: <span class="pageFirst">701</span>&ndash;<span class="pageLast">704</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jc.2002-021161">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12574202">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXhtlCht7w%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000180915300032">Web of Science&reg; Times Cited: 92</a></li></ul></li><li id="bph13439-bib-0003"><cite id="bph13439-cit-0004"><span class="author">Asakawa A</span>, <span class="author">Inui A</span>, <span class="author">Kaga T</span>, <span class="author">Yuzuriha H</span>, <span class="author">Nagata T</span>, <span class="author">Ueno N</span>, <em>et al.</em> (<span class="pubYear">2001</span>). <span class="articleTitle">Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin.</span> <span class="journalTitle">Gastroenterol</span> <span class="vol">120</span>: <span class="pageFirst">337</span>&ndash;<span class="pageLast">345</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1053/gast.2001.22158">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=11159873">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXhtlKlt7Y%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000166705000005">Web of Science&reg; Times Cited: 772</a></li></ul></li><li id="bph13439-bib-0004"><cite id="bph13439-cit-0005"><span class="author">Banks WA</span>, <span class="author">Tsch&ouml;p M</span>, <span class="author">Robinson SM</span>, <span class="author">Heiman ML</span> (<span class="pubYear">2002</span>). <span class="articleTitle">Extent and direction of ghrelin transport across the blood&ndash;brain barrier is determined by its unique primary structure</span>. <span class="journalTitle">J Pharmacol Exp Ther</span> <span class="vol">302</span>: <span class="pageFirst">822</span>&ndash;<span class="pageLast">827</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1124/jpet.102.034827">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12130749">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD38Xls1Ogtbg%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000176899200053">Web of Science&reg; Times Cited: 345</a></li></ul></li><li id="bph13439-bib-0005"><cite id="bph13439-cit-0006"><span class="author">Barazzoni R</span>, <span class="author">Zanetti M</span>, <span class="author">Ferreira C</span>, <span class="author">Vinci P</span>, <span class="author">Pirulli A</span>, <span class="author">Mucci M</span>, <em>et al.</em> (<span class="pubYear">2007</span>). <span class="articleTitle">Relationships between desacylated and acylated ghrelin and insulin sensitivity in metabolic syndrome</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">92</span>: <span class="pageFirst">3935</span>&ndash;<span class="pageLast">3940</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jc.2006-2527">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17652221">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2sXht1SmtbbL">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000250148400027">Web of Science&reg; Times Cited: 94</a></li></ul></li><li id="bph13439-bib-0006"><cite id="bph13439-cit-0007"><span class="author">Bhattacharya SK</span>, <span class="author">Andrews K</span>, <span class="author">Beveridge R</span>, <span class="author">Cameron KO</span>, <span class="author">Chen C</span>, <span class="author">Dunn M</span>, <em>et al.</em> (<span class="pubYear">2014</span>). <span class="articleTitle">Discovery of PF-5190457, a potent, selective, and orally bioavailable ghrelin receptor inverse agonist clinical candidate</span>. <span class="journalTitle">ACS Med Chem Lett</span> <span class="vol">5</span>: <span class="pageFirst">474</span>&ndash;<span class="pageLast">479</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1021/ml400473x">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=24900864">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC2cXjtVeqsbc%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000335879300007">Web of Science&reg; Times Cited: 12</a></li></ul></li><li id="bph13439-bib-0007"><cite id="bph13439-cit-0008"><span class="author">Blatnik M</span>, <span class="author">Soderstrom CI</span> (<span class="pubYear">2011</span>). <span class="articleTitle">A practical guide for the stabilization of acylghrelin in human blood collections.</span> <span class="journalTitle">Clin Endocrinol (Oxf)</span> <span class="vol">74</span>: <span class="pageFirst">325</span>&ndash;<span class="pageLast">331</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1111/j.1365-2265.2010.03916.x/abstract">Abstract</a></li><li><a href="/doi/10.1111/j.1365-2265.2010.03916.x/full">Article</a></li><li><a href="/doi/10.1111/j.1365-2265.2010.03916.x/epdf" class="readcubeEpdfLink">PDF(306K)</a></li><li><a href="/doi/10.1111/j.1365-2265.2010.03916.x/pdf" class="readcubePdfLink">PDF(306K)</a></li><li><a href="/doi/10.1111/j.1365-2265.2010.03916.x/full?scrollTo=references">References</a></li><li><a href="/resolve/reference/ISI?id=000287093200008">Web of Science&reg; Times Cited: 24</a></li></ul></div></li><li id="bph13439-bib-0008"><cite id="bph13439-cit-0009"><span class="author">Blatnik M</span>, <span class="author">Soderstrom CI</span>, <span class="author">Dysinger M</span>, <span class="author">Fraser SA</span> (<span class="pubYear">2012</span>). <span class="articleTitle">Prandial ghrelin attenuation provides evidence that des-acyl ghrelin may be an artifact of sample handling in human plasma.</span> <span class="journalTitle">Bioanalysis</span> <span class="vol">4</span>: <span class="pageFirst">2447</span>&ndash;<span class="pageLast">2455</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.4155/bio.12.248">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=23157354">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC38Xhs1yns73N">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000312680500010">Web of Science&reg; Times Cited: 7</a></li></ul></li><li id="bph13439-bib-0009"><cite id="bph13439-cit-0010"><span class="author">Broglio F</span>, <span class="author">Arvat E</span>, <span class="author">Benso A</span>, <span class="author">Gottero C</span>, <span class="author">Muccioli G</span>, <span class="author">Papotti M</span>, <em>et al.</em> (<span class="pubYear">2001</span>). <span class="articleTitle">Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">86</span>: <span class="pageFirst">5083</span>&ndash;<span class="pageLast">5086</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jcem.86.10.8098">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=11600590">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXptVartb0%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000171755400086">Web of Science&reg; Times Cited: 419</a></li></ul></li><li id="bph13439-bib-0010"><cite id="bph13439-cit-0011"><span class="author">Broglio F</span>, <span class="author">Arvat E</span>, <span class="author">Benso A</span>, <span class="author">Gottero C</span>, <span class="author">Prodam F</span>, <span class="author">Grottoli S</span>, <em>et al.</em> (<span class="pubYear">2002</span>). <span class="articleTitle">Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">87</span>: <span class="pageFirst">3783</span>&ndash;<span class="pageLast">3790</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jcem.87.8.8749">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12161511">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XmtF2gt70%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000177285400042">Web of Science&reg; Times Cited: 56</a></li></ul></li><li id="bph13439-bib-0011"><cite id="bph13439-cit-0012"><span class="author">Broglio F</span>, <span class="author">Benso A</span>, <span class="author">Gottero C</span>, <span class="author">Prodam F</span>, <span class="author">Gauna C</span>, <span class="author">Filtri L</span>, <em>et al.</em> (<span class="pubYear">2003a</span>). <span class="articleTitle">Nonacylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans</span>. <span class="journalTitle">J Endocrinol Invest</span> <span class="vol">26</span>: <span class="pageFirst">192</span>&ndash;<span class="pageLast">196</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1007/BF03345156">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12809167">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXls1Cls7o%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000183021300003">Web of Science&reg; Times Cited: 75</a></li></ul></li><li id="bph13439-bib-0012"><cite id="bph13439-cit-0013"><span class="author">Broglio F</span>, <span class="author">Benso A</span>, <span class="author">Castiglioni C</span>, <span class="author">Gottero C</span>, <span class="author">Prodam F</span>, <span class="author">Destefanis S</span>, <em>et al.</em> (<span class="pubYear">2003b</span>). <span class="articleTitle">The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">88</span>: <span class="pageFirst">1537</span>&ndash;<span class="pageLast">1542</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jc.2002-021504">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12679436">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXjtFCls7s%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000182211000021">Web of Science&reg; Times Cited: 149</a></li></ul></li><li id="bph13439-bib-0013"><cite id="bph13439-cit-0014"><span class="author">Broglio F</span>, <span class="author">Gottero C</span>, <span class="author">Prodam F</span>, <span class="author">Gauna C</span>, <span class="author">Muccioli G</span>, <span class="author">Papotti M</span>, <em>et al.</em> (<span class="pubYear">2004</span>). <span class="articleTitle">Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">89</span>: <span class="pageFirst">3062</span>&ndash;<span class="pageLast">3065</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jc.2003-031964">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=15181099">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2cXmtlKjsb0%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000221839900084">Web of Science&reg; Times Cited: 203</a></li></ul></li><li id="bph13439-bib-0014"><cite id="bph13439-cit-0015"><span class="author">Burdyga G</span>, <span class="author">Varro A</span>, <span class="author">Dimaline R</span>, <span class="author">Thompson DG</span>, <span class="author">Dockray GJ</span> (<span class="pubYear">2006</span>). <span class="articleTitle">Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance</span>. <span class="journalTitle">Am J Physiol Gastrointest Liver Physiol</span> <span class="vol">290</span>: <span class="pageFirst">G1289</span>&ndash;<span class="pageLast">G1297</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1152/ajpgi.00543.2005">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=16423919">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD28XlvVeisbs%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000237418100025">Web of Science&reg; Times Cited: 101</a></li></ul></li><li id="bph13439-bib-0015"><cite id="bph13439-cit-0016"><span class="author">Burdyga G</span>, <span class="author">de Lartigue G</span>, <span class="author">Raybould HE</span>, <span class="author">Morris R</span>, <span class="author">Dimaline R</span>, <span class="author">Varro A</span>, <em>et al.</em> (<span class="pubYear">2008</span>). <span class="articleTitle">Cholecystokinin regulates expression of Y2 receptors in vagal afferent neurons serving the stomach</span>. <span class="journalTitle">J Neurosci</span> <span class="vol">28</span>: <span class="pageFirst">11583</span>&ndash;<span class="pageLast">11592</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1523/JNEUROSCI.2493-08.2008">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=18987194">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1cXhtlOgt77F">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000260665900016">Web of Science&reg; Times Cited: 42</a></li></ul></li><li id="bph13439-bib-0016"><cite id="bph13439-cit-0017"><span class="author">Burdyga G</span>, <span class="author">Varro A</span>, <span class="author">Dimaline R</span>, <span class="author">Thompson DG</span>, <span class="author">Dockray GJ</span> (<span class="pubYear">2010</span>). <span class="articleTitle">Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype</span>. <span class="journalTitle">Am J Physiol Gastrointest Liver Physiol</span> <span class="vol">299</span>: <span class="pageFirst">G63</span>&ndash;<span class="pageLast">G69</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1152/ajpgi.00059.2010">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=20430875">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC3cXpslSgt7c%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000278792600006">Web of Science&reg; Times Cited: 33</a></li></ul></li><li id="bph13439-bib-0017"><cite id="bph13439-cit-0018"><span class="author">Cameron KO</span>, <span class="author">Bhattacharya SK</span>, <span class="author">Loomis AK</span> (<span class="pubYear">2014</span>). <span class="articleTitle">Small Molecule Ghrelin Receptor Inverse Agonists and Antagonists</span>. <span class="journalTitle">J Med Chem</span> <span class="vol">57</span>: <span class="pageFirst">8671</span>&ndash;<span class="pageLast">8691</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1021/jm5003183">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=25036503">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC2cXhtFyiur3P">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000344977400001">Web of Science&reg; Times Cited: 3</a></li></ul></li><li id="bph13439-bib-0018"><cite id="bph13439-cit-0019"><span class="author">Colombo M</span>, <span class="author">Gregersen S</span>, <span class="author">Xiao J</span>, <span class="author">Hermansen K</span> (<span class="pubYear">2003</span>). <span class="articleTitle">Effects of ghrelin and other neuropeptides (CART, MCH, orexin A and B, and GLP-1) on the release of insulin from isolated rat islets.</span> <span class="journalTitle">Pancreas</span> <span class="vol">27</span>: <span class="pageFirst">161</span>&ndash;<span class="pageLast">166</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1097/00006676-200308000-00009">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12883265">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2cXkvFKgtg%3D%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000185572900009">Web of Science&reg; Times Cited: 70</a></li></ul></li><li id="bph13439-bib-0019"><cite id="bph13439-cit-0020"><span class="author">Costantini VJ</span>, <span class="author">Vicentini E</span>, <span class="author">Sabbatini FM</span>, <span class="author">Valerio E</span>, <span class="author">Lepore S</span>, <span class="author">Tessari M</span>, <em>et al.</em> (<span class="pubYear">2011</span>). <span class="articleTitle">GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs.</span> <span class="journalTitle">Neuroendocrinology</span> <span class="vol">94</span>: <span class="pageFirst">158</span>&ndash;<span class="pageLast">168</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1159/000328968">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=21778696">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC3MXht1yns7%2FJ">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000295158800007">Web of Science&reg; Times Cited: 18</a></li></ul></li><li id="bph13439-bib-0020"><cite id="bph13439-cit-0021"><span class="author">Cummings DE</span>, <span class="author">Purnell JQ</span>, <span class="author">Frayo RS</span>, <span class="author">Schmidova K</span>, <span class="author">Wisse BE</span>, <span class="author">Weigle DS</span> (<span class="pubYear">2001</span>). <span class="articleTitle">A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans</span>. <span class="journalTitle">Diabetes</span> <span class="vol">50</span>: <span class="pageFirst">1714</span>&ndash;<span class="pageLast">1719</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.2337/diabetes.50.8.1714">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=11473029">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3MXlslKnurw%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000170096700005">Web of Science&reg; Times Cited: 1616</a></li></ul></li><li id="bph13439-bib-0021"><cite id="bph13439-cit-0022"><span class="author">Cummings DE</span>, <span class="author">Weigle DS</span>, <span class="author">Frayo RS</span>, <span class="author">Breen PA</span>, <span class="author">Ma MK</span>, <span class="author">Dellinger EP</span>, <em>et al.</em> (<span class="pubYear">2002</span>). <span class="articleTitle">Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery</span>. <span class="journalTitle">N Engl J Med</span> <span class="vol">346</span>: <span class="pageFirst">1623</span>&ndash;<span class="pageLast">1630</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1056/NEJMoa012908">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12023994">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000175728600004">Web of Science&reg; Times Cited: 1295</a></li></ul></li><li id="bph13439-bib-0022"><cite id="bph13439-cit-0023"><span class="author">Curtis MJ</span>, <span class="author">Bond RA</span>, <span class="author">Spina D</span>, <span class="author">Ahluwalia A</span>, <span class="author">Alexander SP</span>, <span class="author">Giembycz MA</span>, <em>et al.</em> (<span class="pubYear">2015</span>). <span class="articleTitle">Curtis experimental design and analysis and their reporting: New guidance for publication in BJP</span>. <span class="journalTitle">Br J Pharmacol</span> <span class="vol">172</span>: <span class="pageFirst">3461</span>&ndash;<span class="pageLast">3471</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1111/bph.12856/abstract">Abstract</a></li><li><a href="/doi/10.1111/bph.12856/full">Full Article (HTML)</a></li><li><a href="/doi/10.1111/bph.12856/epdf" class="readcubeEpdfLink">PDF(499K)</a></li><li><a href="/doi/10.1111/bph.12856/pdf" class="readcubePdfLink">PDF(499K)</a></li><li><a href="/doi/10.1111/bph.12856/references">References</a></li><li><a href="/resolve/reference/ISI?id=000356976300001">Web of Science&reg; Times Cited: 21</a></li></ul></div></li><li id="bph13439-bib-0023"><cite id="bph13439-cit-0024"><span class="author">Damdindorj B</span>, <span class="author">Dezaki K</span>, <span class="author">Kurashina T</span>, <span class="author">Sone H</span>, <span class="author">Rita R</span>, <span class="author">Kakei M</span>, <em>et al.</em> (<span class="pubYear">2012</span>). <span class="articleTitle">Exogenous and endogenous ghrelin counteracts GLP-1 action to stimulate cAMP signaling and insulin secretion in islet B-cells</span>. <span class="journalTitle">FEBS Lett</span> <span class="vol">586</span>: <span class="pageFirst">2555</span>&ndash;<span class="pageLast">2562</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1016/j.febslet.2012.06.034/abstract">Abstract</a></li><li><a href="/doi/10.1016/j.febslet.2012.06.034/full">Article</a></li><li><a href="/doi/10.1016/j.febslet.2012.06.034/epdf" class="readcubeEpdfLink">PDF(479K)</a></li><li><a href="/doi/10.1016/j.febslet.2012.06.034/pdf" class="readcubePdfLink">PDF(479K)</a></li><li><a href="/doi/10.1016/j.febslet.2012.06.034/full?scrollTo=references">References</a></li><li><a href="/resolve/reference/ISI?id=000306694800054">Web of Science&reg; Times Cited: 11</a></li></ul></div></li><li id="bph13439-bib-0024"><cite id="bph13439-cit-0025"><span class="author">Damjanovic SS</span>, <span class="author">Lalic NM</span>, <span class="author">Pesko PM</span>, <span class="author">Petakov MS</span>, <span class="author">Jotic A</span>, <span class="author">Miljic D</span>, <em>et al.</em> (<span class="pubYear">2006</span>). <span class="articleTitle">Acute effects of ghrelin on insulin secretion and glucose disposal rate in gastrectomized patients</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">91</span>: <span class="pageFirst">2574</span>&ndash;<span class="pageLast">2581</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jc.2005-1482">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=16621911">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD28XntFWgt78%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000238840600020">Web of Science&reg; Times Cited: 37</a></li></ul></li><li id="bph13439-bib-0025"><cite id="bph13439-cit-0026"><span class="author">Dardzi&#x144;ska JA</span>, <span class="author">Ma&#x142;gorzewicz S</span>, <span class="author">Kaska &#x141;</span>, <span class="author">Proczko M</span>, <span class="author">Stefaniak T</span>, <span class="author">Stankiewicz M</span>, <em>et al.</em> (<span class="pubYear">2014</span>). <span class="articleTitle">Fasting and postprandial acyl and desacyl ghrelin levels in obese and non-obese subjects.</span> <span class="journalTitle">Endokrynol Pol</span> <span class="vol">65</span>: <span class="pageFirst">377</span>&ndash;<span class="pageLast">381</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/PMED?id=25301488">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000343852800007">Web of Science&reg; Times Cited: 1</a></li></ul></li><li id="bph13439-bib-0026"><cite id="bph13439-cit-0027"><span class="author">Date Y</span>, <span class="author">Murakami N</span>, <span class="author">Toshinai K</span>, <span class="author">Matsukura S</span>, <span class="author">Niijima A</span>, <span class="author">Matsuo H</span>, <em>et al.</em> (<span class="pubYear">2002</span>). <span class="articleTitle">The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats</span>. <span class="journalTitle">Gastroenterology</span> <span class="vol">123</span>: <span class="pageFirst">1120</span>&ndash;<span class="pageLast">1128</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1053/gast.2002.35954">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12360474">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD38Xotl2gu7s%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000178415800024">Web of Science&reg; Times Cited: 639</a></li></ul></li><li id="bph13439-bib-0027"><cite id="bph13439-cit-0028"><span class="author">Date Y</span> (<span class="pubYear">2012</span>). <span class="articleTitle">Ghrelin and the vagus nerve</span>. <span class="journalTitle">Methods Enzymol</span> <span class="vol">514</span>: <span class="pageFirst">261</span>&ndash;<span class="pageLast">269</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/B978-0-12-381272-8.00016-7">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=22975058">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC3sXotFyksLs%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000310244000016">Web of Science&reg; Times Cited: 10</a></li></ul></li><li id="bph13439-bib-0028"><cite id="bph13439-cit-0029"><span class="author">Depoortere I</span>, <span class="author">Thijs T</span>, <span class="author">Peeters T</span> (<span class="pubYear">2006</span>). <span class="articleTitle">The contractile effect of the ghrelin receptor antagonist, <span class="smallCaps">d</span>-Lys3-GHRP-6, in rat fundic strips is mediated through 5-HT receptors.</span> <span class="journalTitle">Eur J Pharmacol</span> <span class="vol">537</span>: <span class="pageFirst">160</span>&ndash;<span class="pageLast">165</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.ejphar.2006.03.043">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=16631731">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD28XktVegtrg%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000237889000023">Web of Science&reg; Times Cited: 32</a></li></ul></li><li id="bph13439-bib-0029"><cite id="bph13439-cit-0030"><span class="author">Dezaki K</span>, <span class="author">Hosoda H</span>, <span class="author">Kakei M</span>, <span class="author">Hashiguchi S</span>, <span class="author">Watanabe M</span>, <span class="author">Kangawa K</span>, <em>et al.</em> (<span class="pubYear">2004</span>). <span class="articleTitle">Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in &beta;-cells: implication in the glycemic control in rodents</span>. <span class="journalTitle">Diabetes</span> <span class="vol">53</span>: <span class="pageFirst">3142</span>&ndash;<span class="pageLast">3151</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.2337/diabetes.53.12.3142">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=15561944">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2cXhtVOls7nN">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000225328100014">Web of Science&reg; Times Cited: 187</a></li></ul></li><li id="bph13439-bib-0030"><cite id="bph13439-cit-0031"><span class="author">Dezaki K</span>, <span class="author">Kakei M</span>, <span class="author">Yada T</span> (<span class="pubYear">2007</span>). <span class="articleTitle">Ghrelin uses G&alpha;i2 and activates Kv channels to attenuate glucose-induced Ca2+ signaling and insulin release in islet &beta;-cells: novel signal transduction of ghrelin</span>. <span class="journalTitle">Diabetes</span> <span class="vol">56</span>: <span class="pageFirst">2319</span>&ndash;<span class="pageLast">2327</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.2337/db07-0345">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17575083">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2sXhtV2gs7fI">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000249304500016">Web of Science&reg; Times Cited: 70</a></li></ul></li><li id="bph13439-bib-0031"><cite id="bph13439-cit-0032"><span class="author">Dezaki K</span>, <span class="author">Sone H</span>, <span class="author">Yada T</span> (<span class="pubYear">2008</span>). <span class="articleTitle">Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis</span>. <span class="journalTitle">Pharmacol Ther</span> <span class="vol">118</span>: <span class="pageFirst">239</span>&ndash;<span class="pageLast">249</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.pharmthera.2008.02.008">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=18433874">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1cXlslOrsLw%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000256571300006">Web of Science&reg; Times Cited: 84</a></li></ul></li><li id="bph13439-bib-0032"><cite id="bph13439-cit-0033"><span class="author">Dezaki K</span>, <span class="author">Damdindorj B</span>, <span class="author">Sone H</span>, <span class="author">Dyachok O</span>, <span class="author">Tengholm A</span>, <span class="author">Gylfe E</span>, <em>et al.</em> (<span class="pubYear">2011</span>). <span class="articleTitle">Ghrelin attenuates cAMP-PKA signaling to evoke insulinostatic cascade in islet &beta;-cells.</span> <span class="journalTitle">Diabetes</span> <span class="vol">60</span>: <span class="pageFirst">2315</span>&ndash;<span class="pageLast">2324</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.2337/db11-0368">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=21788571">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC3MXhtFymsbjI">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000294699600014">Web of Science&reg; Times Cited: 25</a></li></ul></li><li id="bph13439-bib-0033"><cite id="bph13439-cit-0034"><span class="author">Egido EM</span>, <span class="author">Rodriguez-Gallardo J</span>, <span class="author">Silvestre RA</span>, <span class="author">Marco J</span> (<span class="pubYear">2002</span>). <span class="articleTitle">Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion</span>. <span class="journalTitle">Eur J Endocrinol</span> <span class="vol">146</span>: <span class="pageFirst">241</span>&ndash;<span class="pageLast">244</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1530/eje.0.1460241">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=11834435">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XhvVemsr8%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000178742800015">Web of Science&reg; Times Cited: 195</a></li></ul></li><li id="bph13439-bib-0034"><cite id="bph13439-cit-0035"><span class="author">Esler WP</span>, <span class="author">Rudolph J</span>, <span class="author">Claus TH</span>, <span class="author">Tang W</span>, <span class="author">Barucci N</span>, <span class="author">Brown SE</span>, <em>et al.</em> (<span class="pubYear">2007</span>). <span class="articleTitle">Small molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss</span>. <span class="journalTitle">Endocrinol</span> <span class="vol">148</span>: <span class="pageFirst">5175</span>&ndash;<span class="pageLast">5185</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/en.2007-0239">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17656463">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2sXht1aju7jO">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000250444000008">Web of Science&reg; Times Cited: 115</a></li></ul></li><li id="bph13439-bib-0035"><cite id="bph13439-cit-0036"><span class="author">Gauna C</span>, <span class="author">Meyler FM</span>, <span class="author">Janssen JA</span>, <span class="author">Delhanty PJ</span>, <span class="author">Abribat T</span>, <span class="author">van Koetsveld P</span>, <em>et al.</em> (<span class="pubYear">2004</span>). <span class="articleTitle">Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">89</span>: <span class="pageFirst">5035</span>&ndash;<span class="pageLast">5042</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jc.2004-0363">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=15472202">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2cXovVems7k%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000224326300039">Web of Science&reg; Times Cited: 132</a></li></ul></li><li id="bph13439-bib-0036"><cite id="bph13439-cit-0037"><span class="author">Gnanapavan S</span>, <span class="author">Kola B</span>, <span class="author">Bustin SA</span>, <span class="author">Morris DG</span>, <span class="author">McGee P</span>, <span class="author">Fairclough P</span>, <em>et al.</em> (<span class="pubYear">2002</span>). <span class="articleTitle">The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">87</span>: <span class="pageFirst">2988</span>&ndash;<span class="pageLast">2991</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jcem.87.6.8739">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12050285">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XkvFaqsbo%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000176241000086">Web of Science&reg; Times Cited: 837</a></li></ul></li><li id="bph13439-bib-0037"><cite id="bph13439-cit-0038"><span class="author">Grabauskas G</span>, <span class="author">Wu X</span>, <span class="author">Lu Y</span>, <span class="author">Heldsinger A</span>, <span class="author">Song I</span>, <span class="author">Zhou SY</span>, <em>et al.</em> (<span class="pubYear">2015</span>). <span class="articleTitle">KATP channels in the nodose ganglia mediate the orexigenic actions of ghrelin</span>. <span class="journalTitle">J Physiol</span> <span class="vol">593</span>: <span class="pageFirst">3973</span>&ndash;<span class="pageLast">3989</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1113/JP270788/abstract">Abstract</a></li><li><a href="/doi/10.1113/JP270788/full">Article</a></li><li><a href="/doi/10.1113/JP270788/epdf" class="readcubeEpdfLink">PDF(1207K)</a></li><li><a href="/doi/10.1113/JP270788/pdf" class="readcubePdfLink">PDF(1207K)</a></li><li><a href="/doi/10.1113/JP270788/full?scrollTo=references">References</a></li><li><a href="/resolve/reference/ISI?id=000360769900022">Web of Science&reg; Times Cited: 1</a></li></ul></div></li><li id="bph13439-bib-0038"><cite id="bph13439-cit-0039"><span class="author">Halem HA</span>, <span class="author">Taylor JE</span>, <span class="author">Dong JZ</span>, <span class="author">Shen Y</span>, <span class="author">Datta R</span>, <span class="author">Abizaid A</span>, <em>et al.</em> (<span class="pubYear">2005</span>). <span class="articleTitle">A novel growth hormone secretagogue 1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain</span>. <span class="journalTitle">Neuroendocrinol</span> <span class="vol">81</span>: <span class="pageFirst">339</span>&ndash;<span class="pageLast">349</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1159/000088796">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=16210868">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2MXhtFGhtLbK">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000232875600006">Web of Science&reg; Times Cited: 60</a></li></ul></li><li id="bph13439-bib-0039"><cite id="bph13439-cit-0040"><span class="author">Holst B</span>, <span class="author">Cygankiewicz A</span>, <span class="author">Jensen TH</span>, <span class="author">Ankersen M</span>, <span class="author">Schwartz TW</span> (<span class="pubYear">2003</span>). <span class="articleTitle">High constitutive signaling of the ghrelin receptor &ndash; identification of a potent inverse agonist</span>. <span class="journalTitle">Mol Endocrinol</span> <span class="vol">17</span>: <span class="pageFirst">2201</span>&ndash;<span class="pageLast">2210</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/me.2003-0069">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12907757">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXoslKgtbc%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000186273700007">Web of Science&reg; Times Cited: 247</a></li></ul></li><li id="bph13439-bib-0040"><cite id="bph13439-cit-0041"><span class="author">Homaee HM</span>, <span class="author">Moradi F</span>, <span class="author">Azarbayjani MA</span>, <span class="author">Peeri M</span> (<span class="pubYear">2011</span>). <span class="articleTitle">Relationships between acylated ghrelin with growth hormone, insulin resistance, lipid profile, and cardio respiratory function in lean and obese men</span>. <span class="journalTitle">J Res Med Sci</span> <span class="vol">16</span>: <span class="pageFirst">1612</span>&ndash;<span class="pageLast">1618</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/PMED?id=22973371">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000299585800014">Web of Science&reg; Times Cited: 2</a></li></ul></li><li id="bph13439-bib-0041"><cite id="bph13439-cit-0042"><span class="author">Inui A</span>, <span class="author">Asakawa A</span>, <span class="author">Bowers CY</span>, <span class="author">Mantovani G</span>, <span class="author">Laviano A</span>, <span class="author">Meguid MM</span>, <em>et al.</em> (<span class="pubYear">2004</span>). <span class="articleTitle">Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ.</span> <span class="journalTitle">FASEB J</span> <span class="vol">18</span>: <span class="pageFirst">439</span>&ndash;<span class="pageLast">456</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1096/fj.03-0641rev">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=15003990">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2cXisFSrs7Y%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000220522800037">Web of Science&reg; Times Cited: 214</a></li></ul></li><li id="bph13439-bib-0042"><cite id="bph13439-cit-0043"><span class="author">Jia YD</span>, <span class="author">Chen X</span>, <span class="author">Tang M</span>, <span class="author">Jiang ZY</span> (<span class="pubYear">2008</span>). <span class="articleTitle">Expression of growth hormone secretatgogue receptor type 1A in visceral vagal and spinal afferent pathways</span>. <span class="journalTitle">Sheng Li Xue Bao</span> <span class="vol">60</span>: <span class="pageFirst">149</span>&ndash;<span class="pageLast">155</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/PMED?id=18288371">PubMed</a></li></ul></li><li id="bph13439-bib-0043"><cite id="bph13439-cit-0044"><span class="author">Kageyama H</span>, <span class="author">Funahashi H</span>, <span class="author">Hirayama M</span>, <span class="author">Takenoya F</span>, <span class="author">Kita T</span>, <span class="author">Kato S</span>, <em>et al.</em> (<span class="pubYear">2005</span>). <span class="articleTitle">Morphological analysis of ghrelin and its receptor distribution in the rat pancreas.</span> <span class="journalTitle">Regul Pept</span> <span class="vol">126</span>: <span class="pageFirst">67</span>&ndash;<span class="pageLast">71</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.regpep.2004.08.031">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=15620416">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2cXhtFGhsb3L">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000226423900011">Web of Science&reg; Times Cited: 74</a></li></ul></li><li id="bph13439-bib-0044"><cite id="bph13439-cit-0045"><span class="author">Kakei M</span>, <span class="author">Yada T</span>, <span class="author">Nakagawa A</span>, <span class="author">Nakabayashi H</span> (<span class="pubYear">2002</span>). <span class="articleTitle">Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons</span>. <span class="journalTitle">Auton Neurosci</span> <span class="vol">102</span>: <span class="pageFirst">39</span>&ndash;<span class="pageLast">44</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/S1566-0702(02)00182-0">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12492134">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXptFyr">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000179475400006">Web of Science&reg; Times Cited: 45</a></li></ul></li><li id="bph13439-bib-0045"><cite id="bph13439-cit-0046"><span class="author">Kapur S</span>, <span class="author">Seeman P</span> (<span class="pubYear">2000</span>). <span class="articleTitle">Antipsychotic agents differ in how fast they come off the dopamine D<sub>2</sub> receptors. Implications for atypical antipsychotic action</span>. <span class="journalTitle">J Psychiatry Neurosci</span> <span class="vol">25</span>: <span class="pageFirst">161</span>&ndash;<span class="pageLast">166</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/PMED?id=10740989">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000085944900008">Web of Science&reg; Times Cited: 176</a></li></ul></li><li id="bph13439-bib-0046"><cite id="bph13439-cit-0047"><span class="author">Kilkenny C</span>, <span class="author">Browne W</span>, <span class="author">Cuthill IC</span>, <span class="author">Emerson M</span>, <span class="author">Altman DG</span> (<span class="pubYear">2010</span>). <span class="articleTitle">NC3Rs Reporting Guidelines Working Group</span>. <span class="journalTitle">Br J Pharmacol</span> <span class="vol">160</span>: <span class="pageFirst">1577</span>&ndash;<span class="pageLast">1579</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1111/j.1476-5381.2010.00872.x/abstract">Abstract</a></li><li><a href="/doi/10.1111/j.1476-5381.2010.00872.x/full">Full Article (HTML)</a></li><li><a href="/doi/10.1111/j.1476-5381.2010.00872.x/epdf" class="readcubeEpdfLink">PDF(222K)</a></li><li><a href="/doi/10.1111/j.1476-5381.2010.00872.x/pdf" class="readcubePdfLink">PDF(222K)</a></li><li><a href="/doi/10.1111/j.1476-5381.2010.00872.x/references">References</a></li><li><a href="/resolve/reference/ISI?id=000279616400002">Web of Science&reg; Times Cited: 783</a></li></ul></div></li><li id="bph13439-bib-0047"><cite id="bph13439-cit-0048"><span class="author">Lankisch TO</span>, <span class="author">Tsunoda Y</span>, <span class="author">Lu Y</span>, <span class="author">Owyang C</span> (<span class="pubYear">2002</span>). <span class="articleTitle">Characterization of CCK(A) receptor affintity states and Ca(2+) signal transduction in vagal nodose ganglia</span>. <span class="journalTitle">Am J Physiol Gastrointest Liver Physiol</span> <span class="vol">282</span>: <span class="pageFirst">G1002</span>&ndash;<span class="pageLast">G1008</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1152/ajpgi.00313.2001">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12016125">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000175620100011">Web of Science&reg; Times Cited: 25</a></li></ul></li><li id="bph13439-bib-0048"><cite id="bph13439-cit-0049"><span class="author">le Roux CW</span>, <span class="author">Neary NM</span>, <span class="author">Halsey TJ</span>, <span class="author">Small CJ</span>, <span class="author">Martinez-Isla AM</span>, <span class="author">Ghatei MA</span>, <em>et al.</em> (<span class="pubYear">2005</span>). <span class="articleTitle">Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy.</span> <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">90</span>: <span class="pageFirst">4521</span>&ndash;<span class="pageLast">4524</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jc.2004-2537">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=15914532">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2MXnvVWltLc%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000231068500015">Web of Science&reg; Times Cited: 137</a></li></ul></li><li id="bph13439-bib-0049"><cite id="bph13439-cit-0050"><span class="author">Lucidi P</span>, <span class="author">Murdolo G</span>, <span class="author">Di Loreto C</span>, <span class="author">Parlanti N</span>, <span class="author">De Cicco A</span>, <span class="author">Fatone C</span>, <em>et al.</em> (<span class="pubYear">2005</span>). <span class="articleTitle">Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations</span>. <span class="journalTitle">Nutr Metab Cardiovasc Dis</span> <span class="vol">15</span>: <span class="pageFirst">410</span>&ndash;<span class="pageLast">417</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.numecd.2005.02.006">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=16314227">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000234152700004">Web of Science&reg;</a></li></ul></li><li id="bph13439-bib-0050"><cite id="bph13439-cit-0051"><span class="author">McGrath JC</span>, <span class="author">Lilley E</span> (<span class="pubYear">2015</span>). <span class="articleTitle">Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP</span>. <span class="journalTitle">Br J Pharmacol</span> <span class="vol">172</span>: <span class="pageFirst">3189</span>&ndash;<span class="pageLast">3193</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1111/bph.12955/abstract">Abstract</a></li><li><a href="/doi/10.1111/bph.12955/full">Full Article (HTML)</a></li><li><a href="/doi/10.1111/bph.12955/epdf" class="readcubeEpdfLink">PDF(252K)</a></li><li><a href="/doi/10.1111/bph.12955/pdf" class="readcubePdfLink">PDF(252K)</a></li><li><a href="/doi/10.1111/bph.12955/references">References</a></li><li><a href="/resolve/reference/ISI?id=000356693500001">Web of Science&reg; Times Cited: 18</a></li></ul></div></li><li id="bph13439-bib-0051"><cite id="bph13439-cit-0052"><span class="author">Mear Y</span>, <span class="author">Enjalbert A</span>, <span class="author">Thirion S</span> (<span class="pubYear">2013</span>). <span class="articleTitle">GHS-R1A constitutive activity and its physiological relevance</span>. <span class="journalTitle">Front Neurosci</span> <span class="vol">7</span>: <span class="pageFirst">1</span>&ndash;<span class="pageLast">7</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.3389/fnins.2013.00087">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=23386807">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000346567300087">Web of Science&reg; Times Cited: 5</a></li></ul></li><li id="bph13439-bib-0052"><cite id="bph13439-cit-0053"><span class="author">Mihalic JT</span>, <span class="author">Kim YJ</span>, <span class="author">Lizarzaburu M</span>, <span class="author">Chen X</span>, <span class="author">Deignan J</span>, <span class="author">Wanska M</span>, <em>et al.</em> (<span class="pubYear">2012</span>). <span class="articleTitle">Discovery of a new class of ghrelin receptor antagonists</span>. <span class="journalTitle">Bioorg Med Chem Lett</span> <span class="vol">22</span>: <span class="pageFirst">2046</span>&ndash;<span class="pageLast">2051</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.bmcl.2012.01.014">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=22305493">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC38XhvVGntbs%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000300451200042">Web of Science&reg; Times Cited: 13</a></li></ul></li><li id="bph13439-bib-0053"><cite id="bph13439-cit-0054"><span class="author">Moens K</span>, <span class="author">Heimberg H</span>, <span class="author">Flamez D</span>, <span class="author">Huypens P</span>, <span class="author">Quartier E</span>, <span class="author">Ling Z</span>, <em>et al.</em> (<span class="pubYear">1996</span>). <span class="articleTitle">Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.</span> <span class="journalTitle">Diabetes</span> <span class="vol">45</span>: <span class="pageFirst">257</span>&ndash;<span class="pageLast">261</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.2337/diab.45.2.257">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=8549871">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DyaK28XjslWnsrw%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=A1996TR89800019">Web of Science&reg; Times Cited: 172</a></li></ul></li><li id="bph13439-bib-0054"><cite id="bph13439-cit-0055"><span class="author">Moradi F</span>, <span class="author">Azarbayjani MA</span>, <span class="author">Peeri M</span> (<span class="pubYear">2011</span>). <span class="articleTitle">Relationships between acylated ghrelin with growth hormone, insulin resistance, lipid profile, and cardio respiratory function in lean and obese men</span>. <span class="journalTitle">J Res Med Sci</span> <span class="vol">16</span>: <span class="pageFirst">1612</span>&ndash;<span class="pageLast">1618</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/PMED?id=22973371">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000299585800014">Web of Science&reg; Times Cited: 2</a></li></ul></li><li id="bph13439-bib-0055"><cite id="bph13439-cit-0056"><span class="author">Motulsky HJ</span>, <span class="author">Mahan LC</span> (<span class="pubYear">1984</span>). <span class="articleTitle">The kinetics of competitive radioligand binding predicted by the law of mass action</span>. <span class="journalTitle">Mol Pharmacol</span> <span class="vol">25</span>: <span class="pageFirst">1</span>&ndash;<span class="pageLast">9</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/PMED?id=6708928">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=A1984RZ24600001">Web of Science&reg; Times Cited: 183</a></li></ul></li><li id="bph13439-bib-0056"><cite id="bph13439-cit-0057"><span class="author">Moulin A</span>, <span class="author">Brunel L</span>, <span class="author">Boeglin D</span>, <span class="author">Demange L</span>, <span class="author">Ryan J</span>, <span class="author">M'kadmi C</span>, <em>et al.</em> (<span class="pubYear">2013</span>). <span class="articleTitle">The 1,2,4-triazole as a scaffold for the design of ghrelin receptor ligands: development of JMV 2959, a potent antagonist.</span> <span class="journalTitle">Amino Acids</span> <span class="vol">44</span>: <span class="pageFirst">301</span>&ndash;<span class="pageLast">314</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1007/s00726-012-1355-2">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=22798076">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC3sXhtFyhs78%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000313794600001">Web of Science&reg; Times Cited: 19</a></li></ul></li><li id="bph13439-bib-0057"><cite id="bph13439-cit-0058"><span class="author">Page AJ</span>, <span class="author">Slattery JA</span>, <span class="author">Milte C</span>, <span class="author">Laker R</span>, <span class="author">O'Donnell T</span>, <span class="author">Dorian C</span>, <em>et al.</em> (<span class="pubYear">2007</span>). <span class="articleTitle">Ghrelin selectively reduces mechanosensitivity of upper gastrointestinal vagal afferents.</span> <span class="journalTitle">Am J Physiol Gastrointest Liver Physiol</span> <span class="vol">292</span>: <span class="pageFirst">G1376</span>&ndash;<span class="pageLast">G1384</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1152/ajpgi.00536.2006">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17290011">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2sXls1yiurs%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000247935800021">Web of Science&reg; Times Cited: 35</a></li></ul></li><li id="bph13439-bib-0058"><cite id="bph13439-cit-0059"><span class="author">Pagotto U</span>, <span class="author">Gambineri A</span>, <span class="author">Vicennati V</span>, <span class="author">Heiman ML</span>, <span class="author">Tsch&ouml;p M</span>, <span class="author">Pasquali R</span> (<span class="pubYear">2002</span>). <span class="articleTitle">Plasma ghrelin obesity and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">87</span>: <span class="pageFirst">5625</span>&ndash;<span class="pageLast">5629</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jc.2002-020776">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12466363">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XpslWnur8%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000179976300043">Web of Science&reg; Times Cited: 122</a></li></ul></li><li id="bph13439-bib-0059"><cite id="bph13439-cit-0060"><span class="author">Pakhtusova N</span>, <span class="author">Zaostrovskaya L</span>, <span class="author">Lindstr&ouml;m P</span>, <span class="author">Larsson-Nyr&eacute;n G</span> (<span class="pubYear">2003</span>). <span class="articleTitle">Cell-specific Ca(2+) responses in glucose-stimulated single and aggregated beta-cells</span>. <span class="journalTitle">Cell Calcium</span> <span class="vol">34</span>: <span class="pageFirst">121</span>&ndash;<span class="pageLast">129</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/S0143-4160(03)00027-7">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12810054">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXks1akt7s%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000183876100002">Web of Science&reg; Times Cited: 6</a></li></ul></li><li id="bph13439-bib-0060"><cite id="bph13439-cit-0061"><span class="author">Pasternak A</span>, <span class="author">Goble SD</span>, <span class="author">deJesus RK</span>, <span class="author">Hreniuk DL</span>, <span class="author">Chung CC</span>, <span class="author">Tota MR</span>, <em>et al.</em> (<span class="pubYear">2009</span>). <span class="articleTitle">Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl)phenyl]benzene sulfonamide ghrelin receptor antagonists</span>. <span class="journalTitle">Bioorg Med Chem Lett</span> <span class="vol">19</span>: <span class="pageFirst">6237</span>&ndash;<span class="pageLast">6240</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.bmcl.2009.08.076">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=19767208">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1MXht1GmurjF">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000270561300055">Web of Science&reg; Times Cited: 16</a></li></ul></li><li id="bph13439-bib-0061"><cite id="bph13439-cit-0062"><span class="author">Patel K</span>, <span class="author">Dixit VD</span>, <span class="author">Lee JH</span>, <span class="author">Kim JW</span>, <span class="author">Schaffer EM</span>, <span class="author">Nguyen D</span>, <em>et al.</em> (<span class="pubYear">2012a</span>). <span class="articleTitle">Identification of ghrelin receptor blocker, <span class="smallCaps">d</span>-[Lys3] GHRP-6 as a CXCR4 receptor antagonist</span>. <span class="journalTitle">Int J Biol Sci</span> <span class="vol">8</span>: <span class="pageFirst">108</span>&ndash;<span class="pageLast">117</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.7150/ijbs.8.108">CrossRef</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC38Xis1aksw%3D%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000301059700010">Web of Science&reg; Times Cited: 10</a></li></ul></li><li id="bph13439-bib-0062"><cite id="bph13439-cit-0063"><span class="author">Patel K</span>, <span class="author">Dixit VD</span>, <span class="author">Lee JH</span>, <span class="author">Kim JW</span>, <span class="author">Schaffer EM</span>, <span class="author">Nguyen D</span>, <em>et al.</em> (<span class="pubYear">2012b</span>). <span class="articleTitle">The GHS-R blocker <span class="smallCaps">d</span>-[Lys3] GHRP-6 serves as CCR5 chemokine receptor antagonist.</span> <span class="journalTitle">Int J Med Sci</span> <span class="vol">9</span>: <span class="pageFirst">51</span>&ndash;<span class="pageLast">58</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.7150/ijms.9.51">CrossRef</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC38Xoslyl">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000298013100009">Web of Science&reg; Times Cited: 9</a></li></ul></li><li id="bph13439-bib-0063"><cite id="bph13439-cit-0064"><span class="author">Pawson AJ</span>, <span class="author">Sharman JL</span>, <span class="author">Benson HE</span>, <span class="author">Faccenda E</span>, <span class="author">Alexander SP</span>, <span class="author">Buneman OP</span>, et al. , NC-IUPHAR(<span class="pubYear">2014</span>). <span class="articleTitle">The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands</span>. <span class="journalTitle">Nucleic Acids Res</span> <span class="vol">42</span>: <span class="pageFirst">D1098</span>&ndash;<span class="pageLast">D1106</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1093/nar/gkt1143">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=24234439">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC2cXosF2i">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000331139800161">Web of Science&reg; Times Cited: 569</a></li></ul></li><li id="bph13439-bib-0064"><cite id="bph13439-cit-0065"><span class="author">Peng Z</span>, <span class="author">Xiaolei Z</span>, <span class="author">Al-Sanaban H</span>, <span class="author">Chengrui X</span>, <span class="author">Shengyi Y</span> (<span class="pubYear">2012</span>). <span class="articleTitle">Ghrelin inhibits inulin release by regulating the expression of inwardly rectifying potassium channel 6.2 in islets</span>. <span class="journalTitle">Am J Med Sci</span> <span class="vol">343</span>: <span class="pageFirst">215</span>&ndash;<span class="pageLast">219</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1097/MAJ.0b013e31824390b9">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=22270395">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000300767600008">Web of Science&reg;</a></li></ul></li><li id="bph13439-bib-0065"><cite id="bph13439-cit-0066"><span class="author">Perdon&agrave; E</span>, <span class="author">Faggioni F</span>, <span class="author">Buson A</span>, <span class="author">Sabbatini FM</span>, <span class="author">Corti C</span>, <span class="author">Corsi M</span> (<span class="pubYear">2011</span>). <span class="articleTitle">Pharmacological characterization of the ghrelin receptor antagonist, GSK1614343 in rat RC-4B/C cells natively expressing GHS type 1a receptors.</span> <span class="journalTitle">Eur J Pharmacol</span> <span class="vol">650</span>: <span class="pageFirst">178</span>&ndash;<span class="pageLast">183</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.ejphar.2010.10.042">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=21034740">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC3cXhsFehurnN">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000285893800024">Web of Science&reg; Times Cited: 11</a></li></ul></li><li id="bph13439-bib-0066"><cite id="bph13439-cit-0067"><span class="author">Puleo L</span>, <span class="author">Marini P</span>, <span class="author">Avallone R</span>, <span class="author">Zanchet M</span>, <span class="author">Bandiera S</span>, <span class="author">Baroni M</span>, <em>et al.</em> (<span class="pubYear">2012</span>). <span class="articleTitle">Synthesis and pharmacological evaluation of indolinone derivatives as novel ghrelin receptor antagonists</span>. <span class="journalTitle">Bioorg Med Chem Lett</span> <span class="vol">20</span>: <span class="pageFirst">5623</span>&ndash;<span class="pageLast">5636</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.bmc.2012.07.018">CrossRef</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC38Xht1SktL3M">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000308808700033">Web of Science&reg; Times Cited: 10</a></li></ul></li><li id="bph13439-bib-0067"><cite id="bph13439-cit-0068"><span class="author">Reimer MK</span>, <span class="author">Pacini G</span>, <span class="author">Ahr&eacute;n B</span> (<span class="pubYear">2003</span>). <span class="articleTitle">Dose-dependent inhibition by ghrelin of insulin secretion in the mouse</span>. <span class="journalTitle">Endocrinology</span> <span class="vol">144</span>: <span class="pageFirst">916</span>&ndash;<span class="pageLast">921</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/en.2002-220819">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12586768">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXhslCqsbw%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000181173900020">Web of Science&reg; Times Cited: 186</a></li></ul></li><li id="bph13439-bib-0068"><cite id="bph13439-cit-0069"><span class="author">Richelson E</span>, <span class="author">Souder T</span> (<span class="pubYear">2000</span>). <span class="articleTitle">Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds</span>. <span class="journalTitle">Life Sci</span> <span class="vol">68</span>: <span class="pageFirst">29</span>&ndash;<span class="pageLast">39</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/S0024-3205(00)00911-5">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=11132243">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3cXos1Wjsrw%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000165624600004">Web of Science&reg; Times Cited: 395</a></li></ul></li><li id="bph13439-bib-0069"><cite id="bph13439-cit-0070"><span class="author">Rodr&iacute;guez A</span>, <span class="author">G&oacute;mez-Ambrosi J</span>, <span class="author">Catal&aacute;n V</span>, <span class="author">Gil MJ</span>, <span class="author">Becerril S</span>, <span class="author">S&aacute;inz N</span>, <em>et al.</em> (<span class="pubYear">2009</span>). <span class="articleTitle">Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes</span>. <span class="journalTitle">Int J Obes (Lond)</span> <span class="vol">33</span>: <span class="pageFirst">541</span>&ndash;<span class="pageLast">552</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1038/ijo.2009.40">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=19238155">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1MXls1eltrs%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000265889700005">Web of Science&reg; Times Cited: 86</a></li></ul></li><li id="bph13439-bib-0070"><cite id="bph13439-cit-0071"><span class="author">Roth CL</span>, <span class="author">Reinehr T</span>, <span class="author">Schernthaner GH</span>, <span class="author">Kopp HP</span>, <span class="author">Kriwanek S</span>, <span class="author">Schernthaner G</span> (<span class="pubYear">2008</span>). <span class="articleTitle">Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery</span>. <span class="journalTitle">Obes Surg</span> <span class="vol">19</span>: <span class="pageFirst">29</span>&ndash;<span class="pageLast">35</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1007/s11695-008-9568-x">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=18521699">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000262281700006">Web of Science&reg; Times Cited: 29</a></li></ul></li><li id="bph13439-bib-0071"><cite id="bph13439-cit-0072"><span class="author">Rudolph J</span>, <span class="author">Esler WP</span>, <span class="author">O'Connor S</span>, <span class="author">Coish PD</span>, <span class="author">Wickens PL</span>, <span class="author">Brands M</span>, <em>et al.</em> (<span class="pubYear">2007</span>). <span class="articleTitle">Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity</span>. <span class="journalTitle">J Med Chem</span> <span class="vol">50</span>: <span class="pageFirst">5202</span>&ndash;<span class="pageLast">5216</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1021/jm070071+">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17887659">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2sXhtVGqt7vK">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000250110700018">Web of Science&reg; Times Cited: 84</a></li></ul></li><li id="bph13439-bib-0072"><cite id="bph13439-cit-0073"><span class="author">Sabbatini FM</span>, <span class="author">Melotto S</span>, <span class="author">Bernasconi G</span>, <span class="author">Bromidge SM</span>, <span class="author">D'Adamo L</span>, <span class="author">Rinaldi M</span>, <em>et al.</em> (<span class="pubYear">2011</span>). <span class="articleTitle">Azabicyclo[3.1.0]hexane-1-carbohydrazides as potent and selective GHSR1a ligands presenting a specific in&#x2005;vivo behavior.</span> <span class="journalTitle">Chem Med Chem</span> <span class="vol">6</span>: <span class="pageFirst">1981</span>&ndash;<span class="pageLast">1985</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1002/cmdc.201100285/abstract">Abstract</a></li><li><a href="/doi/10.1002/cmdc.201100285/full">Full Article (HTML)</a></li><li><a href="/doi/10.1002/cmdc.201100285/epdf" class="readcubeEpdfLink">PDF(263K)</a></li><li><a href="/doi/10.1002/cmdc.201100285/pdf" class="readcubePdfLink">PDF(263K)</a></li><li><a href="/doi/10.1002/cmdc.201100285/references">References</a></li><li><a href="/resolve/reference/ISI?id=000297416900007">Web of Science&reg; Times Cited: 8</a></li></ul></div></li><li id="bph13439-bib-0073"><cite id="bph13439-cit-0074"><span class="author">Sakata I</span>, <span class="author">Yamazaki M</span>, <span class="author">Inoue K</span>, <span class="author">Hayashi Y</span>, <span class="author">Kangawa K</span>, <span class="author">Sakai T</span> (<span class="pubYear">2003</span>). <span class="articleTitle">Growth hormone secretagogue receptor expression in the cells of the stomach-projected afferent nerve in the rat nodose ganglion.</span> <span class="journalTitle">Neurosci Lett</span> <span class="vol">342</span>: <span class="pageFirst">183</span>&ndash;<span class="pageLast">186</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/S0304-3940(03)00294-5">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12757895">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD3sXjvFahurs%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000183093200012">Web of Science&reg; Times Cited: 90</a></li></ul></li><li id="bph13439-bib-0074"><cite id="bph13439-cit-0075"><span class="author">Sakata I</span>, <span class="author">Sakai T</span> (<span class="pubYear">2010</span>). <span class="articleTitle">Ghrelin Cells in the Gastrointestinal Tract</span>. <span class="journalTitle">Intern J Peptides</span> <span class="vol">2010</span>: <span class="pageFirst">945056</span>&ndash;<span class="pageLast">945063</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1155/2010/945056">CrossRef</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC3cXhtlKqtLjI">CAS</a></li></ul></li><li id="bph13439-bib-0075"><cite id="bph13439-cit-0076"><span class="author">Sanger GJ</span>, <span class="author">Broad J</span>, <span class="author">Andrews PL</span> (<span class="pubYear">2013</span>). <span class="articleTitle">The relationship between gastric motility and nausea: gastric prokinetic agents as treatments.</span> <span class="journalTitle">Eur J Pharmacol</span> <span class="vol">715</span>: <span class="pageFirst">10</span>&ndash;<span class="pageLast">14</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.ejphar.2013.06.031">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=23831391">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC3sXht1ShsrbK">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000324025700002">Web of Science&reg; Times Cited: 13</a></li></ul></li><li id="bph13439-bib-0076"><cite id="bph13439-cit-0077"><span class="author">Sato M</span>, <span class="author">Nakahara K</span>, <span class="author">Miyazato M</span>, <span class="author">Kangawa K</span>, <span class="author">Murakami N</span> (<span class="pubYear">2007</span>). <span class="articleTitle">Regulation of GH secretagogue receptor gene expression in the rat nodose ganglion.</span> <span class="journalTitle">J Endocrinol</span> <span class="vol">194</span>: <span class="pageFirst">41</span>&ndash;<span class="pageLast">46</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1677/JOE-06-0078">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17592019">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2sXptV2ntLo%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000248408000005">Web of Science&reg; Times Cited: 11</a></li></ul></li><li id="bph13439-bib-0077"><cite id="bph13439-cit-0078"><span class="author">Schellekens H</span>, <span class="author">Dinan TG</span>, <span class="author">Cryan JF</span>, <em>et al.</em> (<span class="pubYear">2010</span>). <span class="articleTitle">Lean mean fat reducing &ldquo;ghrelin&rdquo; machine: hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity</span>. <span class="journalTitle">Neuropharm</span> <span class="vol">58</span>: <span class="pageFirst">2</span>&ndash;<span class="pageLast">16</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.neuropharm.2009.06.024">CrossRef</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1MXhtlGitrnK">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000273051700002">Web of Science&reg; Times Cited: 39</a></li></ul></li><li id="bph13439-bib-0078"><cite id="bph13439-cit-0079"><span class="author">Sun Y</span>, <span class="author">Asnicar M</span>, <span class="author">Saha PK</span>, <span class="author">Chan L</span>, <span class="author">Smith RG</span> (<span class="pubYear">2006</span>). <span class="articleTitle">Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice</span>. <span class="journalTitle">Cell Metabol</span> <span class="vol">3</span>: <span class="pageFirst">379</span>&ndash;<span class="pageLast">386</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/j.cmet.2006.04.004">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=16679295">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD28XltF2isLc%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000237650200010">Web of Science&reg; Times Cited: 187</a></li></ul></li><li id="bph13439-bib-0079"><cite id="bph13439-cit-0080"><span class="author">Swartz EM</span>, <span class="author">Browning KN</span>, <span class="author">Travagli RA</span>, <span class="author">Holmes GM</span> (<span class="pubYear">2014</span>). <span class="articleTitle">Ghrelin increases vagally mediated gastric activity by central sites of action</span>. <span class="journalTitle">Neurogastroenterol Motil</span> <span class="vol">26</span>: <span class="pageFirst">272</span>&ndash;<span class="pageLast">282</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1111/nmo.12261/abstract">Abstract</a></li><li><a href="/doi/10.1111/nmo.12261/full">Full Article (HTML)</a></li><li><a href="/doi/10.1111/nmo.12261/epdf" class="readcubeEpdfLink">PDF(579K)</a></li><li><a href="/doi/10.1111/nmo.12261/pdf" class="readcubePdfLink">PDF(579K)</a></li><li><a href="/doi/10.1111/nmo.12261/references">References</a></li><li><a href="/resolve/reference/ISI?id=000329791100014">Web of Science&reg; Times Cited: 5</a></li></ul></div></li><li id="bph13439-bib-0080"><cite id="bph13439-cit-0081"><span class="author">Tong J</span>, <span class="author">Prigeon RL</span>, <span class="author">Davis HW</span>, <span class="author">Bidlingmaier M</span>, <span class="author">Kahn SE</span>, <span class="author">Cummings DE</span>, <em>et al.</em> (<span class="pubYear">2010</span>). <span class="articleTitle">Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans</span>. <span class="journalTitle">Diabetes</span> <span class="vol">59</span>: <span class="pageFirst">2145</span>&ndash;<span class="pageLast">2151</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.2337/db10-0504">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=20584998">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BC3cXht12kurbP">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000281612000009">Web of Science&reg; Times Cited: 108</a></li></ul></li><li id="bph13439-bib-0081"><cite id="bph13439-cit-0082"><span class="author">Van Name M</span>, <span class="author">Giannini C</span>, <span class="author">Santoro N</span>, <span class="author">Jastreboff AM</span>, <span class="author">Kubat J</span>, <span class="author">Li F</span>, <em>et al.</em> (<span class="pubYear">2015</span>). <span class="articleTitle">Blunted suppression of acyl-ghrelin in response to fructose ingestion in obese adolescents: the role of insulin resistance</span>. <span class="journalTitle">Obesity</span> <span class="vol">23</span>: <span class="pageFirst">653</span>&ndash;<span class="pageLast">661</span>.</cite><div class="internalReferences"><div><span class="directLinkLabel">Direct Link:</span></div><ul><li><a href="/doi/10.1002/oby.21019/abstract">Abstract</a></li><li><a href="/doi/10.1002/oby.21019/full">Full Article (HTML)</a></li><li><a href="/doi/10.1002/oby.21019/epdf" class="readcubeEpdfLink">PDF(585K)</a></li><li><a href="/doi/10.1002/oby.21019/pdf" class="readcubePdfLink">PDF(585K)</a></li><li><a href="/doi/10.1002/oby.21019/references">References</a></li><li><a href="/resolve/reference/ISI?id=000350249700022">Web of Science&reg;</a></li></ul></div></li><li id="bph13439-bib-0082"><cite id="bph13439-cit-0083"><span class="author">Vestergaard ET</span>, <span class="author">Hansen TK</span>, <span class="author">Gormsen LC</span>, <span class="author">Jakobsen P</span>, <span class="author">Moller N</span>, <span class="author">Christiansen JS</span>, <em>et al.</em> (<span class="pubYear">2007</span>). <span class="articleTitle">Clinical pharmacokinetics and metabolic effects</span>. <span class="journalTitle">Am J Physiol Endocrinol Metab</span> <span class="vol">292</span>: <span class="pageFirst">E1829</span>&ndash;<span class="pageLast">E1836</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1152/ajpendo.00682.2006">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=17311892">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD2sXmvF2mtbg%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000247939100038">Web of Science&reg; Times Cited: 46</a></li></ul></li><li id="bph13439-bib-0083"><cite id="bph13439-cit-0084"><span class="author">Vestergaard ET</span>, <span class="author">Djurhuus CB</span>, <span class="author">Gjedsted J</span>, <span class="author">Nielsen S</span>, <span class="author">M&oslash;ller N</span>, <span class="author">Holst JJ</span>, <em>et al.</em> (<span class="pubYear">2008a</span>). <span class="articleTitle">Acute effects of ghrelin administration on glucose and lipid metabolism</span>. <span class="journalTitle">J Clin Endocinol Metabol</span> <span class="vol">93</span>: <span class="pageFirst">438</span>&ndash;<span class="pageLast">444</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jc.2007-2018">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=18042651">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1cXit1SntL8%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000253165800017">Web of Science&reg; Times Cited: 41</a></li></ul></li><li id="bph13439-bib-0084"><cite id="bph13439-cit-0085"><span class="author">Vestergaard ET</span>, <span class="author">Gormsen LC</span>, <span class="author">Jessen N</span>, <span class="author">Lund S</span>, <span class="author">Hansen TK</span>, <span class="author">Moller N</span>, <em>et al.</em> (<span class="pubYear">2008b</span>). <span class="articleTitle">Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling</span>. <span class="journalTitle">Diabetes</span> <span class="vol">57</span>: <span class="pageFirst">3205</span>&ndash;<span class="pageLast">3210</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.2337/db08-0025">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=18776138">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1MXhsleisbo%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000261312800007">Web of Science&reg; Times Cited: 72</a></li></ul></li><li id="bph13439-bib-0085"><cite id="bph13439-cit-0086"><span class="author">Volante M</span>, <span class="author">Allia E</span>, <span class="author">Gugliotta P</span>, <span class="author">Funaro A</span>, <span class="author">Broglio F</span>, <span class="author">Deghenghi R</span>, <em>et al.</em> (<span class="pubYear">2002</span>). <span class="articleTitle">Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">87</span>: <span class="pageFirst">1300</span>&ndash;<span class="pageLast">1308</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jcem.87.3.8279">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=11889202">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD38XitlWnsL8%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000174620600056">Web of Science&reg; Times Cited: 245</a></li></ul></li><li id="bph13439-bib-0086"><cite id="bph13439-cit-0087"><span class="author">Wei JY</span>, <span class="author">Wang YH</span> (<span class="pubYear">2000</span>). <span class="articleTitle">Effect of CCK pretreatment on the CCK sensitivity of rat polymodal gastric vagal afferent in vitro</span>. <span class="journalTitle">Am J Physiol Endocrinol Metab</span> <span class="vol">279</span>: <span class="pageFirst">E695</span>&ndash;<span class="pageLast">E706</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/PMED?id=10950839">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000088830300027">Web of Science&reg; Times Cited: 11</a></li></ul></li><li id="bph13439-bib-0087"><cite id="bph13439-cit-0088"><span class="author">White HK</span>, <span class="author">Petrie CD</span>, <span class="author">Landschulz W</span>, <span class="author">MacLean D</span>, <span class="author">Taylor A</span>, <span class="author">Lyles K</span>, <em>et al.</em> (<span class="pubYear">2009</span>). <span class="articleTitle">Effects of an oral growth hormone secretagogue in older adults</span>. <span class="journalTitle">J Clin Endocrinol Metab</span> <span class="vol">94</span>: <span class="pageFirst">1198</span>&ndash;<span class="pageLast">1206</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1210/jc.2008-0632">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=19174493">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1MXksFaitLw%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000265145100025">Web of Science&reg; Times Cited: 46</a></li></ul></li><li id="bph13439-bib-0088"><cite id="bph13439-cit-0089"><span class="author">Wierup N</span>, <span class="author">Svensson H</span>, <span class="author">Mulder H</span>, <span class="author">Sundler F</span> (<span class="pubYear">2002</span>). <span class="articleTitle">The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas</span>. <span class="journalTitle">Regul Pept</span> <span class="vol">107</span>: <span class="pageFirst">63</span>&ndash;<span class="pageLast">69</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1016/S0167-0115(02)00067-8">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=12137967">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD38Xls1WlsLw%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000177707200008">Web of Science&reg; Times Cited: 242</a></li></ul></li><li id="bph13439-bib-0089"><cite id="bph13439-cit-0090"><span class="author">Wierup N</span>, <span class="author">Sundler F</span> (<span class="pubYear">2005</span>). <span class="articleTitle">Ultrastructure of islet ghrelin cells in the human fetus</span>. <span class="journalTitle">Cell Tissue Res</span> <span class="vol">319</span>: <span class="pageFirst">423</span>&ndash;<span class="pageLast">428</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1007/s00441-004-1044-x">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=15668796">PubMed</a>,</li><li><a href="/resolve/reference/ISI?id=000227232300008">Web of Science&reg; Times Cited: 34</a></li></ul></li><li id="bph13439-bib-0090"><cite id="bph13439-cit-0091"><span class="author">Woll PJ</span>, <span class="author">Rozengurt E</span> (<span class="pubYear">1988</span>). <span class="articleTitle">[<span class="smallCaps">d</span>-Arg1,<span class="smallCaps">d</span>-Phe5,<span class="smallCaps">d</span>-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3&nbsp;T3 cells, inhibits the growth of human small cell lung cancer cells in vitro</span>. <span class="journalTitle">Proc Natl Acad Sci U S A</span> <span class="vol">85</span>: <span class="pageFirst">1859</span>&ndash;<span class="pageLast">1863</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.1073/pnas.85.6.1859">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=2450349">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DyaL1cXktFOnsLo%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=A1988M590700030">Web of Science&reg; Times Cited: 176</a>,</li><li><a href="/resolve/reference/ADS?id=1988PNAS...85.1859W">ADS</a></li></ul></li><li id="bph13439-bib-0091"><cite id="bph13439-cit-0092"><span class="author">Yakabi K</span>, <span class="author">Kawashima J</span>, <span class="author">Kato S</span> (<span class="pubYear">2008</span>). <span class="articleTitle">Ghrelin and gastric acid secretion</span>. <span class="journalTitle">World J Gastroenterol</span> <span class="vol">14</span>: <span class="pageFirst">6334</span>&ndash;<span class="pageLast">6338</span>.</cite><ul class="externalReferences"><li><a href="/resolve/reference/XREF?id=10.3748/wjg.14.6334">CrossRef</a>,</li><li><a href="/resolve/reference/PMED?id=19009648">PubMed</a>,</li><li><a href="/resolve/reference/CAS?id=1:CAS:528:DC%2BD1MXis1eltLo%3D">CAS</a>,</li><li><a href="/resolve/reference/ISI?id=000261057300012">Web of Science&reg; Times Cited: 21</a></li></ul></li></ul></div><div id="supp-info"><div class="headingCont"><h3 id="bph13439-supInfo-0001">Supporting Information</h3></div><ol class="jumpList"><li><a href="#leftBorder">Top of page</a></li><li><a href="#abstract">Abstract</a></li><li><a href="#bph13439-sec-0005">Tables of Links</a></li><li><a href="#bph13439-sec-0006">Introduction</a></li><li><a href="#bph13439-sec-0007">Methods</a></li><li><a href="#bph13439-sec-0013">Results</a></li><li><a href="#bph13439-sec-0018">Discussion</a></li><li><a href="#bph13439-sec-0019">Acknowledgements</a></li><li><a href="#bph13439-sec-0020">Author contributions</a></li><li><a href="#bph13439-sec-0076">Conflict of interest</a></li><li><a href="#bph13439-sec-0075">Declaration of transparency and scientific rigour</a></li><li><a href="#bph13439-bibl-0001">References</a></li><li><a href="#supp-info">Supporting Information</a></li></ol><div class="para"><p><b>Figure 3SA</b> is an example electrophysiological trace highlighting ghrelin-induced inhibition of a rat gastric vagal afferent firing. Capsaicin was used as a positive inhibitor control to confirm afferent neuron activity. 3SB, Same as A but the average inhibition across 3&ndash;5 preparations.</p></div><table class="supportingInformation"><thead><tr><th id="articleFilename" rowspan="1" colspan="1">Filename</th><th id="articleFormat" rowspan="1" colspan="1">Format</th><th id="articleSize" rowspan="1" colspan="1">Size</th><th id="articleDescription" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr id="bph13439-supitem-0001"><td headers="articleFilename" rowspan="1" colspan="1"><a href="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/supinfo/bph13439-sup-0002-figures_1-2.pdf?v=1&amp;s=e0d55a07c423c2a1fc4c4219f5468589e64a1e69">bph13439-sup-0002-figures_1-2.pdf</a></td><td headers="articleFormat" rowspan="1" colspan="1">PDF document</td><td headers="articleSize" rowspan="1" colspan="1">453K</td><td headers="articleDescription" rowspan="1" colspan="1">Supporting info item</td></tr><tr id="bph13439-supitem-0002"><td headers="articleFilename" rowspan="1" colspan="1"><a href="http://onlinelibrary.wiley.com/store/10.1111/bph.13439/asset/supinfo/bph13439-sup-0001-figures_3.pdf?v=1&amp;s=bb2237206d10a7fc87a01f62c07ac0272e32e8aa">bph13439-sup-0001-figures_3.pdf</a></td><td headers="articleFormat" rowspan="1" colspan="1">PDF document</td><td headers="articleSize" rowspan="1" colspan="1">147K</td><td headers="articleDescription" rowspan="1" colspan="1">Supporting info item</td></tr></tbody></table><p class="suppInfoDisclaimer">Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.</p></div><style xml:space="preserve">
            .overlined {
            text-decoration: overline;
            }
            .struck {
            text-decoration:line-through;
            }
            .underlined {
            text-decoration:underline;
            }
            .doubleUnderlined {
            text-decoration:underline;border-bottom:1px solid #000;
            }
        </style></div>                  <div xmlns="http://www.w3.org/1999/xhtml" class="viewFullArticleAndPdf"><div class="viewFullArticleAndPdfOptions"><a href="http://onlinelibrary.wiley.com/enhanced/doi/10.1111/bph.13439" class="enhancedArticleLink">Enhanced Article (HTML)</a> <a href="/doi/10.1111/bph.13439/epdf" title="Article in pdf format" class="readcubeEpdfLink">Get PDF (473K)</a><a href="/doi/10.1111/bph.13439/pdf" title="Article in pdf format" class="readcubePdfLink">Get PDF (473K)</a></div></div>                   <div id="relatedArticles">     <div class="sectionHeading">         <h3>More content like this</h3>     </div>     <span id="findArticlesHeading">Find more content:</span>     <ul class="findArticles"><li><a href="/advanced/search/results?articleDoi=10.1111/bph.13439&amp;scope=allContent&amp;start=1&amp;resultsPerPage=20" title="Link to articles like this">like this article</a></li></ul>     <span xmlns="http://www.w3.org/1999/xhtml" id="articlesWrittenByHeading">Find more content written by:</span><ul xmlns="http://www.w3.org/1999/xhtml" class="articlesWrittenBy"><li><a title="Link to more articles by J Kong" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;J Kong&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">J Kong</a></li><li><a title="Link to more articles by J Chuddy" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;J Chuddy&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">J Chuddy</a></li><li><a title="Link to more articles by I A Stock" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;I A Stock&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">I A Stock</a></li><li><a title="Link to more articles by P M Loria" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;P M Loria&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">P M Loria</a></li><li><a title="Link to more articles by S V Straub" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;S V Straub&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">S V Straub</a></li><li><a title="Link to more articles by C Vage" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;C Vage&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">C Vage</a></li><li><a title="Link to more articles by K O Cameron" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;K O Cameron&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">K O Cameron</a></li><li><a title="Link to more articles by S K Bhattacharya" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;S K Bhattacharya&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">S K Bhattacharya</a></li><li><a title="Link to more articles by K Lapham" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;K Lapham&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">K Lapham</a></li><li><a title="Link to more articles by K F McClure" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;K F McClure&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">K F McClure</a></li><li><a title="Link to more articles by Y Zhang" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;Y Zhang&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">Y Zhang</a></li><li><a title="Link to more articles by V M Jackson" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;V M Jackson&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">V M Jackson</a></li><li class="lastItem"><a title="Link to more articles by the present authors" href="/advanced/search/results?searchRowCriteria[0].queryString=&quot;J Kong&quot; &quot;J Chuddy&quot; &quot;I A Stock&quot; &quot;P M Loria&quot; &quot;S V Straub&quot; &quot;C Vage&quot; &quot;K O Cameron&quot; &quot;S K Bhattacharya&quot; &quot;K Lapham&quot; &quot;K F McClure&quot; &quot;Y Zhang&quot; &quot;V M Jackson&quot;&amp;searchRowCriteria[0].fieldName=author&amp;start=1&amp;resultsPerPage=20">All Authors</a></li></ul>           </div>         </div>  </div>          </div>  <!-- BEGIN #footer --> <div id="footer">     <div class="l-footer-container">          <div class="l-footer">              <div class="footer-wol">                  <img src="http://onlinelibrarystatic.wiley.com/images/brand/footer-wol-logo.png" class="footer-wol__logo" />                  <div class="footer-wol__primary-nav">                      <ul class="nav"><li><a href="/browse/publications">Publications</a></li><li><a href="/browse/subjects">Browse by Subject</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390229.html">Resources</a></li></ul>                  </div>                  <div class="footer-wol__secondary-nav">                      <ul class="nav"><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390001.html">About Us</a></li><li><a href="http://journalshelp.wiley.com">Help</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-397203.html">Contact Us</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390243.html">Agents</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390236.html">Advertisers</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390242.html">Media</a></li><li><a href="/privacyPolicy">Privacy</a></li><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">Cookies</a></li><li><a href="/termsAndConditions">Terms &amp; Conditions</a></li><li><a href="/siteMap">Site Map</a></li></ul>                  </div>              </div>              <div class="footer-global">                   <div class="footer-global__copyright">                       Copyright &copy; 1999-2016 John Wiley &amp; Sons, Inc. All Rights Reserved.                   </div>                   <div class="footer-global__nav">                       <ul class="nav"><li><a href="http://olabout.wiley.com/WileyCDA/Section/id-390001.html">About Wiley</a></li><li><a href="http://www.wiley.com">Wiley.com</a></li><li><a href="http://www.wileyjobnetwork.com/">Wiley Job Network</a></li><li class="last"><a href="/"><img src="http://onlinelibrarystatic.wiley.com/images/brand/footer-logo.png" alt="Wiley" width="73" height="17" /></a></li></ul>                   </div>              </div>          </div>     </div><!--/ .l-footer-container --> </div> <!-- END #footer -->    <!-- Start Google Analytics --> <script type="text/javascript" xml:space="preserve">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script> <script type="text/javascript" xml:space="preserve">
try {
var pageTracker = _gat._getTracker("UA-11972776-3");
pageTracker._trackPageview();
} catch(err) {}</script> <!-- End Google Analytics -->    </div>         </div><script type="text/javascript" xml:space="preserve">
    (function (wol) {
        wol.config = wol.config || {};

        wol.config.staticAssetUrl = 'http://onlinelibrarystatic.wiley.com/';

        return wol;
    }(window.wol = window.wol || {}));

</script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery/jquery-1.4.2.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery-ui/jquery.ui.core.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery-ui/jquery.ui.widget.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery-ui/jquery.ui.position.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery-ui/jquery.ui.autocomplete.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/ol.widgets.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/ol.reports.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery/jquery.cookie.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery/jquery.bgiframe.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery.fancybox-1.3.1.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery.scrollTo-1.4.2-min.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery.easing-1.3.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery.mousewheel.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/wol.fancybox.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/json2.min.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery/jquery.flot.js" xml:space="preserve"></script><!--[if IE]><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/excanvas.js"></script><![endif]--><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/wol.metrics.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/wol.jquery.plugins.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/wol.treeListMenu.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/wol.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery/jquery.validate.js" xml:space="preserve"></script><script type="text/javascript" src="http://onlinelibrarystatic.wiley.com/js/jquery/jquery.validate.js" xml:space="preserve"></script><script type="text/javascript" xml:space="preserve">_satellite.pageBottom();</script></body></html>